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ABSTRACT
More than two-thirds of the adult population in the United States is classified as
overweight or obese. In order to fully comprehend this rapidly increasing dilemma,
further understanding of the complex phenomena that are involved with obesity and its
many comorbidities is necessary. Chronic inflammation represents a distinctive,
recurrent feature of obesity and has been associated with an increased risk of breast
cancer. Monocyte chemoattractant protein 1 is a crucial component of the inflammatory
process and represents a potential therapeutic treatment target, not only in obesity but
also in breast cancer. Using a monocyte chemoattractant protein deficient model, we
examined the role of this chemokine in the obesogenic inflammatory environment and
results indicate that it can play a protective role in the development of adiposity and
metabolic perturbations in a high fat diet-induced obesity murine model. Additionally,
we examined the role of this chemokine in a model of triple negative breast cancer and
report that deletion significantly reduces tumorigenesis and localized inflammation.
Finally, we tested the central hypothesis that chronic inflammation plays a critical role in
the progression and severity of obesity-induced hormone-dependent breast cancer and
report significant proneoplastic effects. Further understanding of the etiopathogenesis of
obesity and breast cancer has profound, prognostic effects. Therefore, continued research
is required so that novel targeted therapies can be developed in this ever increasing
portion of the population.
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CHAPTER 1
INTRODUCTION
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Over one third of the adult population in the U.S. is obese, resulting in the
continued rise in obesity-related conditions including heart disease, stroke, type-2
diabetes, non-alcoholic fatty liver disease and certain types of cancer (1-6). This global
increase in body mass is an escalating society concern. Concomitant environmental
factors such as sedentary lifestyle, poor diet choices, socioeconomic influences; and less
frequently, genetic disorders involving metabolic outcomes and hormone secretion, result
in weight gain. Although it is well known that obesity can be prevented through healthy
dietary habits and physical activity (7, 8), interventions in a clinical setting have
generally been unsuccessful, especially in the long-term (1, 9). Thus, changing behavior
in this population has proven to be challenging. This has led to an explosion of studies to
understand the pathways driving the pathologic processes associated with obesity so that
therapeutic targets can be identified.
1.1 Mechanisms of Obesity-Induced Inflammation and Insulin Resistance
It is increasingly appreciated that the accumulation of inflammatory cells and
other immune cell types in adipose tissue correlates with a continuing low grade
inflammatory state that ultimately impairs adipocyte function and may contribute to the
development of insulin resistance (5, 10-14). This immuno-metabolic axis modulates the
dysfunctional responses characteristic of obesity including pro-inflammatory cytokine
secretion, immune cell infiltration and disrupted function of tissues involved in glucose
homeostasis, such as adipose tissue, liver and skeletal muscle (12). This obesogenic
environment plays a critical role in the initiation of insulin resistance and altered glucose
metabolism.
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White adipose tissue, one of the two distinct forms of adipose tissue, is the depot
most important to obesity and insulin resistance. It traditionally functions as lipid
storage, storing triacylglycerides following energy excess and deploying these stored
lipids during periods of energy deprivation (15). With obesity and insulin resistance
there is an inapt spillover of triacylglyceride-derived free fatty acids due to the increases
in lipolysis (16) and these free fatty acids can activate inflammatory pathways via tolllike receptors and impair insulin signaling. White adipose tissue is a multi-component
organ composed primarily of adipocytes but can also act as an endocrine organ releasing
cytokines and adipokines to include interleukin (IL)-6, IL-1b, tumor necrosis factor
(TNF)-a, leptin and adiponectin (17). In the insulin resistant state, these inflammatory
cytokines activate several serine kinases, including IkK kinase (IKK) and Jun aminoterminal kinases (JNK). These kinases promote the phosphorylation of serine residues of
the insulin signaling pathway, which can inhibit insulin action (18). White adipose tissue
is unique in its plasticity and can expand with increases in weight gain. This expansion is
accompanied by changes in function of the adipose tissue to include cytokine and
chemokine secretion, immune cell infiltration, hypoxia, cell death, as well as fatty acid
metabolism and storage. Mature adipocytes secrete IL-6, monocyte chemoattractant
protein 1 (MCP-1), leptin, and adiponectin in a regulatory manner, these adipokines and
cytokines can act in a paracrine, endocrine or autocrine manner to regulate glucose and
lipid homeostasis (19).
It seems increasingly probable, given the complexity of pro-inflammatory
signaling pathways, that a combination of cytokine-induced stimuli would elicit greater
effective activation of the inflammation/insulin resistance paradigm than a single entity
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alone. It is known that IL-1, TNF-a, and toll-like receptor 4 (TLR4) converge at the
inhibitor of NF-kB kinase complex (IkB kinase) (20) and that nuclear factor kappa B
(NF-kB) and JNK mitogen-activated protein kinase (MAPK) pathways link obesity,
inflammation, and insulin resistance(21). But what instigates and consequentially
propagates this inflammation?
Reduced ability of the adipose tissue to support the increases in lipids and store
excess fats and an increased hypoxic environment both contribute to the influx of
inflammation that accompanies the obesity phenotype. Adipose tissue hypoxia is a
metabolic stressor that is partially induced by inadequate blood supply reaching the
expanding organ. Tissue inflammation is associated with regions of hypoxia and is also
linked to NF-kB signaling (22). Decreased adipose tissue expandability, leading to free
fatty acid spillover, results in elevated circulating free fatty acids. This results in
enhanced lipid accumulation in peripheral tissues such as the liver and skeletal muscle,
inducing morphological and metabolic alterations leading to an inflamed and insulin
resistant state by various processes.
Inflammation is a crucial mediator in obesity-induced insulin resistance. The
expansion of white adipose tissue with obesity and the corresponding influx of
inflammatory cells, such as macrophages, initiate a cascade of inflammatory events that
directly contribute to an altered glucose response and insulin signaling. Evidence
suggests that the mechanisms driving this pathogenic environment of obese white adipose
tissue are actually a combination of events converging that escalate this pro-inflammatory
state.
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1.2 Monocyte Chemoattractant Protein 1
One such component of this obesogenic environment is MCP-1. MCP-1 (CCL2)
is a member of the C-C chemokine family that bind to G protein coupled receptors to
regulate macrophage recruitment during wound healing, infection, and inflammation (2325) and is the most extensively studied chemokine. MCP-1 was the first discovered
human CC chemokine and is located on chromosome 17 (23). MCP-1 is a small, soluble
chemokine 13kDa in size and shares high sequence homology with other members of the
MCP family (MCP-1, 2, 3 and 4). MCP-1 is expressed in response to a cell stressor, such
as oxidative stress, or growth factor but can also be constitutively expressed by a variety
of cell types including epithelial, smooth muscle, endothelial, fibroblasts, mesangial,
monocytic, astrocytic, and microglial cells (23, 26-28). However, the major source of
MCP-1 are monocytes and macrophages and their activity is regulated by the secretion of
various cytokines (29). In addition, adipocytes have been recognized as an important
source of MCP-1 (30, 31).
MCP-1 modulates cell chemotaxis by binding to G-protein coupled receptors on
the surface of migratory leukocytes that have been targeted for activation. Once the
receptors have been activated, they trigger a well-defined intracellular signaling cascade
that results in the formation of inositol triphosphate, intracellular calcium release and
protein kinase C (PKC) activation (32). MCP-1 binds to the C-C chemokine receptor 2
(CCR2) receptor in target cells that is constitutively expressed in monocytes but only
detectable in T cells after activation (33). Evidence suggests that serine/threonine kinases
are required for MCP-1-stimulated chemotaxis (34), and various kinases have been
implicated in MCP-1 signal transduction; including the MAP kinases ERK1 and ERK2,
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Janus kinase JAK2, the stress activated kinases JNK1 and p38, phospholipase C and two
isoforms of PI3-kinase (p85/p110 and C2α) (35-38). In addition to modulating
chemotactic activity for leukocytes, studies have indicated that MCP-1 is multi-faceted
and can also play a role in tumor metastasis and angiogenesis, the immune and vascular
systems, as well as in modulation of cell proliferation, apoptosis, and protein synthesis
(39).
MCP-1 expression is regulated at the transcriptional level by various inducers
such as TNFa, interferon gamma (IFN-g), platelet derived growth factor (PGDF) and
stress factors (40). In many of these regulatory responses, the pro-inflammatory NF-kB
transcription factor is a key mediator. The increase in NF-kB activity in response to
these inducers is well correlated with mononuclear cell infiltration and expression of
MCP-1 and adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1) and
vascular cellular adhesion molecule-1 (VCAM-1) (41).
MCP-1 has been shown to play a role in many disease pathologies and chronic
expression of MCP-1 contributes to inflammatory diseases including obesity, rheumatoid
arthritis, atherosclerosis, and fibrosis (42-45). Moreover, several studies have shown
MCP-1 to be overexpressed in cancers of the breast and ovary and that increased
expression of MCP-1 in tumor cells correlates with increases in macrophage infiltration
and tumor vascularization (46-48).
1.3 Monocyte Chemoattractant Protein 1 & Obesity
Overnutrition causes cellular stress in hypertrophic adipocytes, resulting in the
release of pro-inflammatory cytokines, free fatty acids and the macrophage-attracting
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chemokine MCP-1 (49, 50). Clinical studies have documented elevated mRNA levels of
MCP-1 and that of its receptor, CCR2, in the visceral adipose tissue and elevated MCP-1
protein levels in the layer of peritoneum that surrounds abdominal organs in obese
subjects. Experimental studies in high fat diet-fed rodents have reported similar trends
with increases in mRNA expression of MCP-1 and its receptor, CCR2, in visceral
adipose tissue. For example, we have reported an increase in mRNA expression levels of
MCP-1 (~8 fold) in epididymal adipose tissue of mice following 16 weeks of
consumption of a high fat diet that was designed to be similar to the standard American
diet (51). Consistent with experimental evidence, increased circulating levels of plasma
MCP-1 are found in obese and type 2 diabetic patients, indicative of increased systemic
levels of inflammation. MCP-1 is predominantly released by immune cells including
macrophages, however, given its recent attention as an adipokine we now know that it is
also produced by adipocytes themselves (52).
Although the tissues and cell types involved in obesity-induced inflammation are
not fully understood, there is increasing interest in the role of adipose tissue macrophages
in these inflammatory changes. Studies in both humans and rodents show increases in
adipose tissue macrophage content correlate with increases in body weight and insulin
resistance (14, 53, 54). Adipose tissue macrophage content is higher in the visceral fat
than the subcutaneous fat in obese subjects and weight loss leads to a reduction in
adipose tissue macrophage content (55). Adipose tissue macrophages provide a potential
link between inflammation and insulin resistance as they are the prominent source of
inflammatory cytokines such as TNF-a and IL-6, which can inhibit insulin action (54,
56).
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While quantitative changes in adipose tissue macrophage content with obesity is
well supported in the literature, very little is known about variations in function and how
these are modified with the development of obesity. Macrophages are characterized by a
remarkable degree of plasticity and show significant heterogeneity in regards to function.
They are able to adapt to a variety of environmental cues and different stimuli activate
macrophages to express distinct patterns of surface markers, chemokines and metabolic
enzymes that ultimately generate the diversity of macrophage function seen in
inflammatory and steady-state settings (57, 58). The classical view presents a highly
simplified M1/M2 phenotype classification (59). M1 or “classically activated”
macrophages possess the cell surface marker CD11c, secrete pro-inflammatory cytokines
and contribute to the induction of insulin resistance (57). Conversely, M2 or
“alternatively activated” macrophages, have a different gene expression profile
characterized by the relatively high expression of surface marker CD206 and antiinflammatory cytokine expression (60). M2 macrophages are believed to participate in
the blockade of inflammatory responses and in the promotion of tissue repair (61).
However, such a system ignores the innumerable variety of phenotypes and has since
been replaced with an understanding of the diverse macrophage population and that
macrophages are likely activated across a continuum of these states. In a high fat dietinduced obesogenic state, circulating Ly6C+ inflammatory monocytes continuously
infiltrate the adipose tissue in a MCP-1-dependent manner and differentiate into adipose
tissue macrophages (62). Under the influence of environmental cues, free fatty acids, and
inflammatory cytokines the recruited monocytes differentiate into pro-inflammatory
adipose tissue macrophages initiating a vicious cycle of inflammation. This paracrine
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loop is recapitulated by free fatty acids released from adipocytes and inflammatory
mediators that elicit the production of even more inflammatory cytokines (such as IL-6,
IL-1b, and TNFa) by the adipose tissue macrophages (63).
1.4 Breast Cancer & Obesity
Breast carcinomas continue to be the most commonly occurring cancer in women
and the second leading cause of cancer-related deaths. Breast cancer incidence and
mortality rates are rapidly increasing in Asian countries such as China and India as the
adoption of a “western” lifestyle continues to increase (64). A 2010 meta-analysis of 43
studies found that obesity at diagnosis is associated with poorer breast cancer specific and
overall survival (65) and links between obesity and an increased risk of breast cancer
recurrence and shorter disease-free survival have also been established (66). Obesity is
not only characterized by increases in the amount of adipose tissue but also changes in
the adipose tissue biology. Multiple molecular changes arising as a consequence of
increased amounts of body fat are likely to contribute to the increased incidence of
neoplasia and worse outcomes in the obese population. These changes include increased
inflammatory cell infiltration, hyperinsulinemia, adipokine imbalances, increased
cytokine and estrogen levels, and elevating insulin-like growth factor 1 (IGF-1) levels.
These proneoplastic changes are likely to contribute to the elevated cancer incidence in
general and worse overall outcomes associated with obesity and breast cancer.
One integrating mechanism that links obesity and breast cancer risk is the role of
chronic inflammation. Chronic inflammation is recognized as an important mediator in
the clinical and biochemical complications associated with obesity and also breast tumor
biology and causation. Inflammation in adipose tissue, with infiltration by macrophages,
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is well known to occur with obesity and its presence in the breast creates local conditions
that favor breast epithelial cell transformation, cancer cell proliferation and invasion as
well as tumor-related neovascularization. Adipose tissue macrophages can comprise up
to 40% of the cells in obese adipose tissue and histologically, this macrophage infiltration
manifests as inflammatory foci known as crown-like structures (67). Initially identified
in visceral fat, these inflammatory foci have recently been observed in breast white
adipose tissue of obese women as the abundance of these crown-like structures generally
increases proportionally with body mass (68).
Breast cancer is a uniquely heterogeneous disease with different biological and
clinical patterns between younger and older women. Thus, menopausal status as a
prognostic factor becomes a topic of scrutiny. In the case of younger women, the link
between body mass and breast cancer risk is more controversial. Some clinical studies in
premenopausal women report a null or inverse association of obesity and breast cancer
risk (69-72), while other investigators report weight gain and central obesity increase the
risk of premenopausal breast cancer (73-77). In postmenopausal women the relationship
is clearer; the majority of evidence supports a direct link between high fat diet-induced
obesity and the risk for certain clinical subtypes of breast cancer (78-95). The molecular
heterogeneity of breast cancers is now well recognized, with at least five different
subtypes identified through molecular profiling (96). With obesity, estrogen and
progesterone hormone-dependent breast cancers are of importance as estrogen signaling
is likely to be a key contributor to obesity-associated breast cancer. Importantly,
activation of estrogen receptor (ER) a-dependent gene expression, as a consequence of
adipose inflammation has been observed in murine mammary fat pads and human breast
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samples (68, 97, 98). Additionally, estrogen metabolites have been proposed to have
carcinogenic effects independent of ER signaling (99).
The primary site for estrogen biosynthesis in premenopausal women is the ovary
but other peripheral sources have increased relative importance in estrogen synthesis. Of
which, the adipose tissue expresses the estrogen synthase cytochrome aromatase p450
(100, 101), which is encoded by the Cyp19 gene, and contributes to estrogen synthesis.
In postmenopausal women, obesity and associated inflammation have been shown to
contribute to increased breast cancer risk as the adipose tissue is the primary source of
estrogen synthesis due to increased aromatase expression (102-104). In support of this
concept, studies link aromatase expression in inflamed adipose tissue of obese women
with the upregulation of proinflammatory mediators, such as macrophages, as aromatase
transcription can be induced by the interaction of TNFa and IL-1b with their receptors.
Breast tissue from obese women and mice have correlated increased expression of TNFa
and IL-1b with increases in aromatase and ERa target genes (68, 97, 98). Regardless of
ER status, dietary-induced chronic inflammation in breast adipose tissue promotes a
localized environment conducive to increased tumor cell proliferation and metastatic
capacity, with enhanced tumor-related angiogenesis. Thus, it is likely that paracrine
interactions between macrophages and other cells types operate on an inflammatory axis
that results in elevated estrogen biosynthesis and expression, however, further delineation
of this axis is required before treatment mechanisms can be established.
1.5 Monocyte Chemoattractant Protein 1 & Breast Cancer
Clinical literature implicates elevations in MCP-1 in the development and
progression of tumorigenesis. The mechanisms linking MCP-1 to cancer has largely

11	
  

been attributed to its role as a powerful monocyte and macrophage chemoattractant, thus
demonstrating its increased ability to recruit macrophages to the tumor
microenvironment. In mammary tumors, high levels of MCP-1 significantly correlate
with increased tumor-associated macrophage accumulation and infiltration into the tumor
environment that can facilitate tumor progression through macrophage-mediated
angiogenesis (105) and through secretion of growth and survival factors (48).
Macrophages are key mediators in the connection between inflammation and
cancer progression and have been shown to play an important role in the development of
tumor-related inflammation and neovascularization. Tumor-associated macrophages
have been reported to represent up to 50% of the tumor mass (106) and have been shown
to possess features involved with proangiogenic capabilities such as the expression of
vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (107) as
well as a potent source of MCP-1 (108), thus leading to continued macrophage
recruitment and enhancement (109). Tumor-associated macrophages are also a source of
potent immunosuppressive molecules, such as IL-10 and prostaglandin E2 (PGE2), that
contribute to tumor evasion from immune surveillance (110). Vascular endothelial cells
also express MCP-1 receptors, and the chemokine stimulates capillary tube formation in
vitro and the entire process of neovascularization in vivo, activity that is independent of
MCP-1 well known role of chemotaxis (109). Recent studies demonstrate that MCP-1
also signals breast cancer cells to regulate survival and invasion (111) as well as promote
primary tumor growth (112).
Cancer-free breast epithelial cells lack expression of MCP-1, while expression is
significantly elevated in both neoplastic and stromal cells within the breast tumor
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microenvironment (108, 113-119). Of these stromal cell types, fibroblasts and
macrophages have been reported to express the highest levels of MCP-1 (115, 117).
Given this evidence, expression of MCP-1 appears to be an acquired feature gained
during tumor development demonstrating its necessity to the establishment and
development of the tumor. A number of studies have reported that MCP-1 is
significantly correlated with high tumor grade and lymph node metastasis as well as
being associated with low levels of differentiation and poor prognosis (115, 120-122).
Evidence indicates that MCP-1 regulates multiple mechanisms of breast cancer
progression and has been shown to be a significant prognostic indicator for breast cancer
prognosis (48). Thus, this demonstrates the value of MCP-1 as a potential therapeutic
target in inflammatory and difficult-to-treat cancers such as triple negative breast cancers.
1.6 Statement of Hypothesis & Aim
Significant advances in understanding the highly complex role of obesity and
immunometabolism have been made in recent years. However, additional research is
needed to fully elucidate this obesity-inflammation-aromatase axis so that potential
biomarker development and targeted inflammatory signaling treatments can be
established.
In these current studies, we tested the central hypothesis that chronic
inflammation plays a critical role in the progression and severity of obesity-induced
insulin resistance and hormone-dependent breast cancer progression. Additionally, we
examined the role of MCP-1 expression in an obesogenic inflammatory environment and
furthermore, the association of this chemokine with mammary tumorigenesis.
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Substantial evidence indicates that obesity is linked to a state of chronic lowgrade inflammation. In our first study, we examined the association of MCP-1
expression and its role on macrophage recruitment in a model of high fat diet-induced
obesity. To test this association, we used a genetic MCP-1 global deletion mouse model
and examined the absence of MCP-1 on adiposity, cellular infiltration, inflammation, and
metabolic dysfunction following high fat diet (HFD) feeding in mice. Contrary to what
we hypothesized, and largely inconsistent with the previously reported findings, we
found that MCP-1 depletion increased adiposity, resulted in exaggerated metabolic
dysfunction, and exacerbated infiltration of inflammatory cells into adipose tissue
following 16 weeks of HFD feedings; thus indicating a protective role of MCP-1
expression in the adipose tissue.
More than 40,000 women in the United States die each year of breast cancer.
Thus identifying novel targets for breast cancer treatment is of upmost clinical
importance. In our second study, we tested the hypothesis that MCP-1 is an important
component in the progression of mammary tumorigenesis and acts to increase
macrophage infiltration into the mammary gland and also via pro-inflammatory
pathways. To test this hypothesis, we introduced a genetic global MCP-1 knockout onto
a triple negative model of breast cancer and examined differences in tumorigenesis.
MCP-1 deficiency significantly decreased mammary tumorigenesis and reduced
inflammation in the mammary gland and tumor; thus, confirming a pro-tumorigenic role
of this chemokine in this model.
More than two-thirds of breast cancer patients have tumors that express estrogen
receptors and increased obesity results in elevated levels of estradiol. Consequently,
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obese women are at a significantly increased risk of developing hormone receptor
positive breast cancers. Our third study focuses on this increased risk and examines
mammary tumorigenesis in response to high fat diet feedings in a transgenic murine
model of tumorigenesis, an experimental model that presents morphological similarities
with human breast cancer. Our results show that chronic consumption of a HFD
increases mammary tumorigenesis and histopathological tumor stage progression in a
premenopausal model of breast cancer.
Taken together, these studies demonstrate that inflammation has emerged as a
leading player in obesity-related pathologies and cancer biology. Obesity provides a
direct link between inflammation and dysregulated metabolism and not surprisingly,
therefore has an emergent role in the etiopathogenesis of breast cancer. Given the
profound clinical implications, more evidence is needed so that targeted therapies can be
developed.
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CHAPTER 2
ROLE OF MONOCYTE CHEMOATTRACTANT PROTEIN-1 ON
INFLAMMATORY PROCESSES AND METABOLIC DYSFUNCTION
FOLLOWING HIGH FAT DIET FEEDINGS IN THE FVB/N STRAIN1

1

	
  Cranford TL, Enos RT, Velazquez KT, McClellan JL, Davis JM, Singh UP, Nagarkatti

M, Nagarkatti PS, Robinson CM, Murphy EA. Role of Monocyte Chemoattractant
Protein-1 on inflammatory processes and metabolic dysfunction following high-fat diet
feedings in the FVB/N strain, Int J Obes, (2016) May;40(5):844-51
Reprinted here with permission from publisher
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Abstract
MCP-1 is known to be an important chemokine for macrophage recruitment. Thus,
targeting MCP-1 may prevent the perturbations associated with macrophage-induced
inflammation in adipose tissue. However, inconsistencies in the available animal
literature have questioned the role of this chemokine in this process. The purpose of this
study was to examine the role of MCP-1 on obesity-related pathologies. Wild-type (WT)
and MCP-1 deficient mice on an FVB/N background were assigned to either low-fat-diet
(LFD) or HFD treatment for a period of 16 weeks. Body weight and body composition
were measured weekly and monthly, respectively. Fasting blood glucose and insulin, and
glucose tolerance were measured at 16 weeks. Macrophages, inflammatory mediators,
and markers of fibrosis were examined in the adipose tissue at sacrifice. As expected,
HFD increased adiposity (body weight, fat mass, fat percent, and adipocyte size),
metabolic dysfunction (impaired glucose metabolism and insulin resistance) macrophage
number (CD11b+F480+ cells, and gene expression of EMR1 and CD11c), inflammatory
mediators (pNFκB and pJNK, and mRNA expression of MCP-1, CCL5, CXCL14, TNFα, and IL-6), and fibrosis (expression of IL-10, IL-13, TGF-β, and MMP2) (P<0.05).
However, contrary to our hypothesis, MCP-1 deficiency exacerbated many of these
responses resulting in a further increase in adiposity (body weight, fat mass, fat percent
and adipocyte size), metabolic dysregulation, macrophage markers (EMR1),
inflammatory cell infiltration, and fibrosis (formation of type I and III collagens, mRNA
expression of IL-10 and MMP2) (P<0.05). These data suggest that MCP-1 is protective
against weight gain, metabolic dysregulation, inflammatory cell infiltration, and fibrosis
in the FVB/N strain in response to HFD feedings.
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2.1 Introduction
Over one third of the adult population in the U.S. is obese, resulting in a rise in
obesity-related conditions including heart disease, stroke, type-2 diabetes, and certain
types of cancer (1-6). Although it is well known that obesity can be prevented through
healthy dietary habits and physical activity (7, 8), interventions in a clinical setting have
generally been unsuccessful, especially in the long-term (1, 9). Thus, changing behavior
in this population has proven to be challenging. This has led to an explosion of studies to
understand the pathways driving the pathologic processes associated with obesity so that
therapeutic targets can be identified.
A pathophysiological mechanism that can link obesity to disease risk is chronic
inflammation. Obesity-associated inflammation is largely mediated by quantitative and
phenotypic changes in adipose tissue macrophages. Approximately 45-60% of adipose
tissue cells express the F4/80 macrophage marker in obese mice, whereas only 10-15% of
cells from lean mice express this marker (14). In addition, adipose tissue macrophages in
obese mice exhibit a pro-inflammatory M1 phenotype, whereas those from lean mice
have an anti-inflammatory M2 phenotype (61, 123). Emerging evidence also associates
macrophages with the dysregulation of metabolic homeostasis given the recent reports
implicating their role in leptin and insulin resistance (124, 125). Thus, targeting
macrophage recruitment may reverse obesity-related pathologies.
As such, several studies have examined the role of chemokines for their ability to
reduce macrophage infiltration in mouse models of diet-induced obesity. Monocyte
chemoattractant protein 1 (MCP-1) is perhaps the most widely investigated chemokine in
this regard. It is increased in white adipose tissue of obese subjects resulting in
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recruitment of bone-derived monocytes, which infiltrate the tissue from circulation (126,
127). Recently, it has been reported that MCP-1 can even induce macrophage cell
division in adipose tissue implants, whereas MCP-1 deficiency in vivo decreases adipose
tissue macrophage proliferation (128). MCP-1 has also been implicated in playing a role
in metabolism; mice engineered to express an MCP-1 transgene in adipose tissue are
reported to be insulin resistant (129). However, while the majority of data supports a role
for MCP-1 on high-fat-diet (HFD) related pathologies there have been some
inconsistencies, at least in the animal literature. For example, Inouye et al., reported no
change in adipose tissue macrophage number in MCP-1 deficient mice following dietinduced obesity but in fact showed that these mice gained more weight, were glucose
intolerant, had mildly increased plasma glucose and were hyperinsulinemic compared
with wild-type mice suggesting a beneficial effect of this chemokine on metabolism
independent of its macrophage recruiting abilities (130). While the inconsistences in the
literature are still largely unexplained, Galastri et al., reported that lack of MCP-1
differently affects inflammation according to the genetic background in a model of dietinduced steatohepatitis (131).
We sought to examine the role of MCP-1 on adiposity, cellular infiltration,
inflammation, and metabolic dysfunction following HFD feeding in mice. This was done
using MCP-1 deficient mice on an FVB/N background, a model that was generated in our
laboratory. The HFD was designed by our research team and has previously been
reported to induce obesity and increase adipose tissue macrophage infiltration following
16 weeks of feedings (51, 132), albeit in the C57BL/6 strain. As expected, we confirmed
an increase in adiposity, metabolic dysfunction, macrophage markers, and inflammation
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with HFD feedings. However, contrary to what we hypothesized, our findings indicate
that MCP-1 deficiency exacerbates many of these responses implicating a beneficial
effect of this chemokine in HFD-related pathologies.

2.2 Materials & Methods
Animals
MCP1-/- mice on the C57BL/6 background and FVB/N wild-type mice were
originally obtained from Jackson Laboratories (Bar Harbor, ME). The FVB/N mice were
crossed with the C57BL/6 MCP1-/- strain, and then back-crossed an additional eight times
to derive the FVB/N MCP1-/- strain. All experimental mice were bred and cared for in
the animal research facility at the University of South Carolina. Male mice were used in
all experiments and were genotyped for MCP-1 using the primer sequences as follows:
mutant GCCAGAGGCCACTTGTGTAG, wild type forward
TGACAGTCCCCAGAGTCACA and common TCATTGGGATCATCTTGCTG. They
were housed, 3-5/cage, maintained on a 12:12-h light-dark cycle in a low stress
environment (22°C, 50% humidity, low noise) and given food and water ad libitum.
Principles of laboratory animal care were followed, and the Institutional Animal Care and
Usage Committee of the University of South Carolina approved all experiments.
Diets
At four weeks of age, wild-type and MCP-1-/- mice were randomly assigned to
either a low-fat-diet (LFD) (n= 7 WT Con, n=7 MCP Con) or a HFD treatment (n=7 WT
HFD, n=8 MCP HFD). The AIN-76A diet was used for the LFD. The HFD was
designed by our laboratory and closely mimics the standard American diet (40% and 12%
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of calories from total fat and saturated fat, respectively) (Bioserv, Frenchtown, NJ) (51,
133). Both diets contained similar vitamin and mineral content. Mice were fed their
respective diets for 16 weeks.
Body weights, food intake, and body composition
Body weight and food intake were monitored weekly. Body composition was
assessed approximately every 4 weeks (age 4, 9, 12, 16, and 20 weeks). Briefly, mice
were placed under anesthesia (isoflurane inhalation) and were assessed for lean mass, fat
mass, and body fat percentage via dual-energy x-ray absorptiometry (DEXA) (Lunar
PIXImus, Madison, WI) (51).
Metabolism
Blood samples were collected from the tail vein after a 5-hour fast during week 16
of dietary treatment. Blood glucose concentrations were determined in whole blood
using a glucometer (Bayer Contour, Michawaka IN). Insulin concentrations were
determined in plasma using an ELISA kit (Mercodia, Uppsala, Sweden). Insulin
resistance was estimated by the homeostatic model assessment (HOMA) index as
follows: insulin resistance index = fasting insulin (µU/mL) x fasting glucose
(mmol/L)/22.5 (134). Glucose tolerance tests were performed after 16 weeks of dietary
treatment on mice fasted for 5 hours. Glucose (1g/kg) was given intraperitoneally and
the blood glucose concentrations were measured intermittingly (0, 15, 30, 60, 90, and 120
minutes) over a two-hour period. Area under the curve (AUC) was calculated using the
trapezoidal rule.
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Tissue collection
Following 16 weeks of dietary treatment, mice were sacrificed for tissue
collection. Epididymal, mesentery, and retroperitoneal fat pads as well as the liver were
removed, weighed, and immediately snap-frozen in liquid nitrogen and stored at -80°C or
fixed in 10% formalin.
Immunohistochemistry
A portion of epididymal adipose tissue was excised from each mouse, fixed
overnight in 10% formalin, dehydrated with alcohol, and embedded in wax. Paraffin
sections were stained with hematoxylin and eosin (H&E). Tissue content of type I and III
collagens was examined using the picro-sirius red stain kit (Abcam, Cambridge, MA,
USA, #150681).
Adipose tissue morphometry
To determine adipocyte size, the surface area of 100 adipocytes were determined
(manual trace) from H&E stained slides using ImageJ software (National Institutes of
Health, Bethesda, MD) (135) and then averaged to represent mean adipocyte size for
each mouse.
Western blots
Epididymal adipose tissue was homogenized in Mueller buffer, which included a
protease inhibitor cocktail (Sigma), 1% glycerophophate (100mM), 0.5% sodium
orthovanadate (5mM) and 1% sodium fluoride (25mM) (51). The protein concentration
was determined using the Bradford method (136). Proteins were fractioned onto
Criterion precast gels (Bio-Rad, Hercules, CA) and were subsequently transferred to a
polyvinylidene difluoride membrane overnight. Membranes were stained with a Ponceau
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S solution to verify equal protein loading and transfer efficiency. Western blot analysis
was performed as previously described using primary antibodies for phosphorylated
(Ser536) and total NFκB p65 (#3033S) as well as phosphorylated (Thr183/Tyr185) and
total JNK (#4671S) (Cell Signaling, Danvers, MA) (137, 138).
Magnetic cell sorting & flow cytometry
Epididymal adipose tissue samples were digested using Collagenase Type II
(1mg/mL) and cRPMI (RPMI, 1% pentastrep, 1% BSA), strained, and centrifuged.
Following lysing, cells were resuspended and centrifuged twice in FACS buffer to create
a single cell suspension. Cells were counted and the cell volume of each sample was
computed prior to pooling samples into each of the four treatment groups. An isolation
buffer (PBS supplemented with 0.5% BSA and 2 mM EDTA) was used to resuspend the
cells and CD11b MACS microbeads (Miltenyi Biotec Inc., San Diego, CA, #130-049601) were used according to manufacturer’s instruction. Cells were separated by
magnetic properties in the column matrix (MACS, Auburn, CA, #130-042-201) and then
resuspended in flow buffer. CD11b positive cells were counted using trypan blue. CD11b
cells were stained for F480+ (EBioscience, San Diego, CA, USA) and analyzed using a
FC 500 (Beckman Coulter, Brea, CA) flow cytometer.
Real-time quantitative PCR
Epididymal adipose tissue was homogenized under liquid nitrogen using a
polytron, and total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA)
and chloroform/isopropyl alcohol extraction. Murine 18s rRNA was used as the
housekeeping gene to normalize all of the data obtained. Quantification of epididymal
adipose tissue mRNA gene expression for macrophage markers (F4/80, CD11c, CD206),
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cytokines (interleukin-6 (IL6), tumor necrosis factor α (TNFα), interleukin-10 (IL10),
and interleukin-13 (IL13)), cell proliferation and differentiation cytokine transforming
growth factor β (TGFβ), chemokines (MCP-1, C-X-C motif chemokine-12 (CXCL12), CX-C motif chemokine-14 (CXCL14), C-C motif ligand-5 (CCL5), and fetuin-A), and
matrix metalloproteinases (matrix metalloproteinase-2 (MMP2), matrix
metalloproteinase-9 (MMP9)), (Applied Biosystems, Foster City, CA) were performed as
previously described (138). Quantitative reverse transcriptase polymerase chain reaction
analysis was carried out as per the manufacturer's instructions using TaqMan Gene
Expression Assays (Applied Biosystems, Foster City, CA). Quantification of mRNA
expression of all target genes was calculated using the 2ΔΔCT method.
Statistical analysis
All data were analyzed using commercial software (GraphPad Software, Prism 6,
La Jolla, CA, USA). Total body weight, body weight percent change, body composition
measurements and the glucose tolerance test were analyzed using a two-way analysis of
variance at each time point. All other data were analyzed using a two-way analysis of
variance. Bonferroni correction was used for all post-hoc analyses. Statistical
significance was set with an α value of P ≤ 0.05. Data are represented as mean ± SEM.

2.3 Results
FVB/N MCP1-/- mice fed a HFD have increased body weight gain and larger
adipocyte size compared to wild-type mice fed the same diet
As expected, the HFD treatment increased body weight beginning at 1 week
following initiation of the HFD treatment and remained elevated through the 16-week
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treatment period (Figures 2.1A & 2.1B; P<0.05). Main effects of genotype were also
observed; interestingly, MCP-1 deficient mice that weighed less than WT mice at
baseline (4 weeks of age) were heavier at 7-12 weeks of HFD treatment (P<0.05; Figure
2.1A). Percent change in body weight is presented to reflect relative changes wherein
MCP-1 deficient mice experienced greater weight gain from 1-16 weeks of age (P<0.05;
Figure 2.1B). A significant interaction was observed for body weight at weeks 9-12 and
weeks 10-11 for total body weight and body weight percent change, respectively
(P<0.05); MCP-1 deficient mice increased body weight only when fed a HFD.
Similar effects were seen for the body composition analysis. A main effect of diet
was seen at 4, 9, 12 and 16 weeks for both body fat (Figure 2.1C) and body fat percent
(Figure 2.1D) (P<0.05), and a main effect of genotype was observed at 9 and 12 weeks
for both of these outcomes (P<0.05). A significant interaction was found at 9 and 12
weeks for both total body fat and body fat percent (P<0.05); the observed increase with
MCP-1 deficiency was dependent on diet treatment. For lean weight, only a main effect
of diet was observed at 12 weeks (Figure 2.1E) (P<0.05).
The HFD treatment increased mean adipocyte size regardless of genotype (Figure
2.1F) (P<0.05). Further, a significant interaction was found as MCP-1 deficient mice fed
a HFD had a significantly larger mean adipocyte size than the wild-type HFD-fed mice
(P<0.05).
Visceral fat depots (epididymal, kidney, mesenteric) and liver were collected at
sacrifice and weighed (Table 1). The HFD treatment increased mass in all fat depots as
well as the liver (P ≤ 0.05). Further, there was a main effect of genotype for the kidney
fat weight and liver weight (P ≤ 0.05); both were heavier in MCP-1 deficient mice.
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In general, there were no differences among HFD-fed mice in weekly food intake
(food consumed by mice in each cage/number of mice in cage) over the course of the
study.
The absence of MCP-1 in FVB/N mice fed a HFD increases insulin resistance and
aggravates glucose metabolism
HFD increased fasting blood glucose (Figure 2.2A) and insulin concentrations,
(Figure 2.2B) as well as the HOMA index (Figure 2.2C) (P ≤ 0.05). In addition, a main
effect for genotype was observed where MCP-1 deficiency increased fasting blood
insulin concentration and the HOMA index (P<0.05). Post-hoc analyses revealed that this
effect occurred within the HFD groups only (P ≤ 0.05). A glucose tolerance test (Figure
2.2D, E) revealed a main effect of diet (0, 15, 30, 60, 90 and 120 min) and genotype (15
and 30 min). Further, an interaction was found where MCP-1 deficient mice within the
HFD treatment displayed poorer glucose metabolism than the wild-type mice at 30, 60,
90 and 120 minutes post-glucose administration (P ≤ 0.05). Consistent with the
aforementioned results, the AUC also revealed a main effect of diet and a significant
interaction between the HFD treatment groups (P ≤ 0.05).
Adipose tissue inflammatory cell infiltration is influenced by HFD consumption
and the absence of MCP-1 in the FVB/N strain
H&E staining revealed increased inflammatory cell infiltration into epididymal fat
(Figure 2.3A). Interestingly however, MCP-1 deficiency exacerbated this response as
there was a further increase in the MCP1-/- HFD group.
These findings were confirmed using flow cytometric analysis (Figure 2.3B); we
report an increase in CD11b+F480+ cells in HFD treated mice (78.7 and 89.8% for HFD
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groups versus 22.6 and 27.6% for LFD groups). Again, this effect appeared to be
worsened with MCP-1-/- within HFD as a further increase in CD11b+F480+ cells was
observed (89.8% versus 78.7%).
RT-qPCR was performed to determine macrophage marker gene expression
(Figure 2.3C). A significant main effect of diet was observed across all 3 markers where
HFD treatment increased EMR1 (overall macrophage), CD11c (M1) and CD206 (M2)
expression (P<0.05). A main effect of genotype was significant for EMR1 only;
consistent with the IHC and FACS data, MCP-1 deficiency increased expression of
EMR1 and post-hoc analyses revealed that this can attributed to an elevation within the
HFD treatment only (P<0.05).
Long-term HFD feeding leads to adipose tissue inflammation but this is not
significantly influenced by MCP-1 in the FVB/N strain
Western blot analysis revealed a main effect of diet on pNFκB (p65) and pJNK
inflammatory pathway activation (P<0.05) (Figure 2.4A-B). Gene expression of the
chemokines MCP-1, CCL5 (Rantes) and CXCL14 were increased with HFD (P<0.05)
and there was a trend for an increase in Fetuin A (P=0.09). Although there was no main
effect of diet for CXCL12, there was a significant interaction where the effect of HFD
was dependent on MCP-1 deficiency (P<0.05). The pro-inflammatory cytokines TNF-α
and IL-6 were significantly upregulated in the HFD groups (P<0.05) (Figure 2.4C) but
there was no effect of genotype and no interactions.
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Prolonged HFD feedings leads to the formation of fibrosis in the adipose tissue of MCP-1
deficient mice on the FVB/N background
A main effect of diet was found across all 3 cytokine markers of fibrosis and
tissue remodeling including IL-10, IL-13 and TGF-β (P<0.05). A main effect of
genotype was observed for IL-10 (P<0.05) as well as a significant interaction between the
wild-type HFD-fed mice and the MCP-1 deficient mice fed the same diet (P<0.05).
There was a main effect of diet for both MMP2 and MMP9 (P<0.05); the mice treated
with the HFD had significant increases in mRNA expression levels of MMP2, and
conversely, decreases in mRNA expression levels of MMP9 (P<0.05) (Figure 2.5A).
Further, for MMP2 there was a main effect of genotype (P<0.05) and also an interaction;
MMP2 was increased in the MCP-1 deficient mice fed a HFD compared to the wild-type
group fed the same diet. Picro-sirius red staining of the epididymal adipose tissue
exhibited a substantial increase in the formation of type I and III collagens in the MCP1-/HFD-fed mice (Figure 2.5B).

2.4 Discussion
Adipose tissue macrophages have been implicated in playing a role in obesityrelated perturbations given their propensity to promote inflammation. MCP-1 is known
to be an important chemokine for macrophage recruitment in various tissues. Thus,
targeting this chemokine may prevent macrophage accumulation and subsequent
inflammation in adipose tissue. While several studies have examined the role of MCP-1
on inflammatory processes in mouse models of obesity, the findings remain ambiguous.
Given this, we sought to examine the importance of MCP-1 on HFD-related pathologies
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using MCP-1 deficient mice on an FVB/N background. As expected, we found an
increase in fat mass, metabolic dysfunction, macrophage markers, and inflammatory
processes with HFD feedings. However, contrary to what we hypothesized, our findings
indicate that MCP-1 deficiency increases adiposity, metabolic dysregulation,
inflammatory cell infiltration, and fibrosis, implicating a potential protective effect of this
chemokine in HFD-related pathologies in this mouse model.
The consequences of HFD feedings has been well characterized in the literature.
In fact, we have reported that the exact HFD used in the current study leads to increased
adiposity, macrophage accumulation and inflammation following 16 weeks of treatment
(51, 137). However, the aforementioned studies were conducted in the C57BL/6 strain
whereas in the current investigation we used mice on the FVB/N background; a strain
that is often implicated as being resistant to diet-induced obesity (139-141). For
example, studies have reported that HFD-feedings using a diet that consisted of 40% or
higher fat content, for a period of 8 weeks, resulted in no changes in bodyweight or
adiposity measurements (139-141). Montgomery et al., performed a similar feeding
schedule for 8 weeks and concluded that there are only marginal changes in bodyweight
and adiposity in FVB/N mice (142). However, not all the results have pointed towards
resistance to diet-induced obesity in the FVB/N strain. For example, Metlakunta el al.,
reported increases in body weight, plasma insulin levels and fat pad weights in FVB/N
mice fed a HFD for 19 weeks (143). The literature undoubtedly implicates straindependent differences in obesity and related outcomes in response to HFD feedings
(142). However, the inconsistences that have been reported within the FVB/N strain, as
well as others, may be due to the duration of HFD feedings, fat content of the diet, sex of
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the mice, housing conditions, and/or differences in gut microbiota. For example, we have
previously reported stark differences in adiposity, macrophage accumulation, and
metabolic outcomes when the content of saturated fat, but not total fat, is altered (51).
Nonetheless, our findings clearly confirm an increase in adiposity, metabolic dysfunction,
macrophage accumulation, and inflammation following 16 weeks on a 40% HFD in the
FVB/N strain.
MCP-1 is strongly linked to macrophage accumulation into adipose tissue and
subsequent inflammation (124, 144). However, inconsistences in mechanistic studies in
mice have questioned the role of this chemokine in this process. While the majority of
the literature supports an influence of MCP-1 on macrophage recruitment and
inflammatory processes in response to HFD feedings, several studies have reported no
effect of MCP-1 and some have even reported that MCP-1 depletion leads to negative
perturbations. Kanda et al., used both MCP-1 overexpression and depletion techniques in
genetically obese and diet-induced obese mice and reported that MCP-1 does, in fact,
contribute to macrophage infiltration and insulin resistance (144). These findings were
consistent with Kamei et al. who reported an increase in macrophage accumulation and
insulin resistance following MCP-1 overexpression in adipose tissue (129). Others have
extended these findings using manipulation of the MCP-1 receptor (C-C motif chemokine
receptor-2 (CCR2) (145). Despite these convincing investigations, several studies have
reported no change in adipose tissue macrophage accumulation or insulin resistance in
mouse models of obesity following interruption of MCP-1 (146-148). We generated an
MCP-1 deficient FVB/N mouse in our lab and were thus interested in furthering the
understanding of this chemokine in obesity-related pathologies given the inconsistencies
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in the current literature. Contrary to what we hypothesized, and largely inconsistent with
the previously reported findings, we found that MCP-1 depletion increased adiposity,
resulted in exaggerated metabolic dysfunction, and exacerbated infiltration of
inflammatory cells into adipose tissue following 16 weeks of HFD feedings. Adipocyte
expansion and sustained inflammation are linked to fibrosis (149). Thus, given the
increase in adipocyte hypertrophy and cell infiltration in MCP-1 deficient mice, we also
measured fibrosis and report a substantial increase in collagens type 1 and III along with
gene expression of select genes likely involved in this process including IL-10 and
MMP2.
It is most likely that the exaggerated increase in metabolic dysfunction,
inflammatory cell infiltration, and fibrosis in the MCP-1 deficient mice occurred in
response to the earlier and more dramatic weight gain following HFD feedings in this
strain. Based on the body composition data, the MCP-1 deficient mice clearly show an
increase in total body fat and body fat percent at 9 weeks and 12 weeks of HFD feedings,
which was no longer significantly different from the wild-type mice at 16 weeks. Thus,
if adiposity is accelerated in MCP-1 deficient mice it seems intuitive that we would
expect subsequent hastening of metabolic dysregulation, immune cell infiltration, and
fibrosis. What is causing this increase in adiposity in the MCP-1 deficient mice is not
clear. It is possible that MCP-1 may be involved in the regulation of adipogenesis,
although there is limited literature to support such a hypothesis. A recent study however,
reported that MCP-1 induced protein (MCP1P) induces adipogenesis resulting in an
increase in the number of adipocytes (150). Based on this, it is plausible that a deficiency
in MCP-1 would decrease adipocyte renewal resulting in hypertrophy of the existing
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adipocytes and an ensuing unfavorable response as observed here. Our findings are
supported by Inouye et al., who reported that depletion of MCP-1 resulted in more weight
gain, glucose intolerance, increased plasma glucose, decreased serum adiponectin, and
hyperinsulinemia compared with wild-type mice, although there were no differences in
adipose tissue macrophage infiltration (130). Similarly, Kirk et al., using a similar MCP1 knockout approach, reported higher levels of a macrophage-specific protein in multiple
fat depots as well as increased adipose tissue weight in MCP-1 deficient mice (148).
A limitation of our study is that we examined only one time-point for the majority
of outcomes; our data is limited to the 16-week time-point – a time-point when there
were no differences in body composition, although differences in percent change of body
weight were still evident. It would have been informative to have measured the influence
of MCP-1 on inflammation and fibrosis at earlier time-points when much larger
differences in body composition were observed to fully evaluate the role of this
chemokine in obesity progression. It is certainly possible that differences in
inflammatory mediators, chemokines, and possibly other parameters, between the groups
would have been detected and/or greater had we measured these outcomes at earlier timepoints.
Our data clearly suggest a necessary role for this chemokine in preventing
obesity-related pathologies, at least in the FVB/N strain. However, given the previous
literature, which is largely confined to the C57BL/6 strain, we performed an additional
study using the C57BL/6 background utilizing the exact same diet and feeding duration.
Although our sample size was limited (n=4-6/group), in general, we observed either no
change or a slightly beneficial effect of MCP-1 depletion on adiposity and inflammation
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following HFD feedings (Figure 2.6). This led us to conclude that lack of MCP-1 can
differentially affect adiposity, metabolic processes, and inflammatory cell recruitment
according to the genetic background. In support of this hypothesis, Galastri et al.,
reported similar strain differences in a mouse model of steatohepatitis in which the
effects of MCP-1 deficiency were markedly different between mice on a C57BL/6
background and those on a Balb/C background (131).
In summary, we report for the first time that MCP-1 is protective against weight
gain, metabolic dysregulation, inflammatory cell infiltration, and fibrosis in the FVB/N
strain in response to HFD feedings. Although MCP-1 is clearly linked to adiposity and
macrophage accumulation, the mechanistic studies that have evaluated this chemokine
remain ambiguous. Future investigations incorporating multiple mouse strains, and
examining several time-points of obesity development are necessary to understand the
role of this chemokine on obesity-related pathologies in order to truly evaluate the
therapeutic potential of MCP-1.
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2.5 Figures & Legends

Figure 2.1:
Body weight characteristics. A. Body weight in grams. B. Body weight represented as
percent change from starting weight. C. Body composition analysis, Body fat in grams. D.
Body fat percentage. E. Lean weight in grams. F. Mean adipocyte size. *main effect of diet,
#main effect of genotype. ^interaction between HFD groups. Data are represented as ± SEM
and representative of two individual experiments, n=7 WT Con, n=7 WT HFD, n=7 MCP
Con, n=8 MCP HFD.
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Figure 2.2:
Metabolic outcomes. A. Fasting blood glucose concentration (mg/dL). B. Fasting blood
insulin concentration (ug/L). C. HOMA Index (n=7 WT Con, n=7 WT HFD, n=7 MCP Con,
n=8 MCP HFD). D-E. Glucose tolerance test performed at 16 weeks of diet treatment (n= 4
WT Con, n=5 WT HFD, n=4 MCP Con, n=5 MCP HFD). *main effect of diet, #main effect
of genotype. ^interaction between HFD groups. Data are represented as ± SEM and
representative of two individual experiments.
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Figure 2.3:
Inflammatory cell population. A. Epididymal fat H&E staining. B. Flow cytometric analysis
of CD11b+F480+ cells. C. Relative gene expression of macrophage markers in epididymal
fat. *main effect of diet, #main effect of genotype. ^interaction between HFD groups. Data
are represented as ± SEM and representative of two individual experiments, n=7 WT Con,
n=7 WT HFD, n=7 MCP Con, n=8 MCP HFD.
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Figure 2.4:
Inflammatory response. A-B. Epididymal fat western blot analysis of inflammatory pathway
activation. C. Relative mRNA expression of inflammatory cytokines and chemokines in
epididymal fat. *main effect of diet, #main effect of genotype. ^interaction between HFD
groups. Data are represented as ± SEM and representative of two individual experiments,
n=7 WT Con, n=7 WT HFD, n=7 MCP Con, n=8 MCP HFD.
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Figure 2.5:
Markers of fibrosis. A. Relative mRNA expression of fibrosis markers in epididymal fat. B.
Picro-sirius red staining of epididymal adipose tissue. *main effect of diet, #main effect of
genotype. ^interaction between HFD groups. Data are represented as ± SEM and
representative of two individual experiments, n=7 WT Con, n=7 WT HFD, n=7 MCP Con,
n=8 MCP HFD.
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Table 2.1:
Animal characteristics, including liver and fat pad weights, separated by mouse genotype
and diet groups. *main effect of diet, #main effect of genotype. ^interaction between HFD
groups. Data are represented as ± SEM and representative of two individual experiments,
n=7 WT Con, n=7 WT HFD, n=7 MCP Con, n=8 MCP HFD.
!

Tissue!Weight!(mg)!
Epididymal)Fat)

WT!Control!
594.4±64.5)

MCP16/6!Control!
595.1±101.5)

Kidney)Fat)

302.3±42.5)

Mesenteric)Fat)

430.9±39.2)

Total)Visceral)Fat)
Liver)

!
!

WT!HFD!

MCP16/6!HFD!

1516.5±114.5*)

1313.3±117.0*)

389.0±78.0)

978.7±56.8*)

1183.5±89.8*#)

431.1±56.7)

1007.0±74.1*)

1137.4±103.1*)

1327.6±141.9)

1415.3±228.0)

3379.9±215.6*)

3634.1±233.6*)

1496.8±68.5)

1667.3±73.6)

1886.6±67.7*)

2213.0±171.8*#)

!
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Figure 2.6:
C57BL/6 study results. A. Bodyweight in grams. B. Bodyweight represented as percent
change from starting weight. C. Fasting blood glucose concentrations (mg/dL). D. Fasting
blood insulin concentrations (ug/L). E. HOMA Index. F. Relative mRNA expression of
inflammatory cytokines and chemokines in epididymal fat. G. Relative mRNA expression of
macrophage markers in epididymal fat. H. Relative mRNA expression of fibrosis markers in
epididymal fat. I. Epididymal fat H&E staining. J. Body composition analysis, Body fat in
grams. K. Body fat percentage. L. Lean weight in grams. *main effect of diet, #main effect
of genotype. ^interaction between HFD groups. Data are represented as ± SEM, n=6 WT
Con, n=5 WT HFD, n=4 MCP Con, n=6 MCP HFD
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CHAPTER 3
LOSS OF MONOCYTE CHEMOATTRACTANT PROTEIN 1
EXPRESSION DECREASES MAMMARY TUMORIGENESIS AND
REDUCES LOCALIZED INFLAMMATION IN THE C3(1)/SV40TAG
TRIPLE NEGATIVE BREAST CANCER MODEL1

1

	
  Cranford TL, Velazquez KT, Enos RT, Bader J, Carson MS, Chatzistamou I, Nagarkatti
M, Murphy EA. Loss of monocyte chemoattractant protein 1 expression decreases
mammary tumorigenesis and reduces localized inflammation in the C3(1)/SV40Tag triple
negative breast cancer model (Submitted to Cancer Biology & Therapy)
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Abstract
Monocyte chemoattractant protein 1 (MCP-1) has been implicated as a major modulator
in the progression of mammary tumorigenesis, largely due to its ability to recruit
macrophages to the tumor microenvironment. Macrophages are key mediators in the
connection between inflammation and cancer progression and have been shown to play
an important role in tumorigenesis. Thus, MCP-1 may be a potential therapeutic target in
inflammatory and difficult-to-treat cancers such as triple negative breast cancer (TNBC).
We examined the effect of MCP-1 depletion on mammary tumorigenesis in a model of
TNBC. Female C3(1)/SV40Tag and C3(1)/SV40Tag MCP-1 deficient mice were
progressed to 12 or 23 weeks of age. Tumor palpations were conducted weekly to
establish crude tumor number and volume characteristics. Tumor statistics for number
and volume, and gene expression of macrophage markers and inflammatory mediators
were measured in the mammary gland and tumor microenvironment at sacrifice. As
expected, MCP-1 depletion resulted in decreased tumorigenesis, indicated by reduced
primary tumor volume and multiplicity, and a delay in tumor progression represented by
histopathological scoring. Deficiency in MCP-1 significantly downregulated expression
of macrophage markers in the mammary gland (Mertk and CD64) and the tumor
microenvironment (CD64), and also reduced expression of inflammatory cytokines in the
mammary gland (TNFa and IL-1b) and the tumor microenvironment (IL-6). These data
support the hypothesis that MCP-1 expression contributes to increased tumorigenesis via
recruitment of macrophages to the tumor environment, thus resulting in increased
inflammatory mediators to assist in mammary tumor progression in a model of TNBC.
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3.1 Introduction
Breast cancer is the most common cancer and the second leading cause of cancer
death among women worldwide (151). In the United States alone, close to 250,000 new
cases of invasive breast cancer will be diagnosed and over 40,000 breast cancer deaths
will occur in the year 2016 (152). The molecular heterogeneity of breast cancers is now
well recognized, with at least five different subtypes identified through molecular
profiling (96). Triple negative breast cancer (TNBC) represents a subtype that more
frequently affects younger women and is associated with a high mortality rate (153, 154).
Triple negative cancers represent between 10-20% of breast cancer cases and are defined
as tumors that lack the estrogen receptor (ER), progesterone receptor (PR) and human
epidermal growth factor receptor type 2 (Her2/neu) that are known to fuel most breast
cancers. TNBC often present as interval cancers and are significantly more aggressive
than tumors of other molecular subtypes (153, 155, 156). Patients with triple negative
cancers have a significantly shorter survival following the first metastatic event (157),
and the majority of deaths occur in the first five years following therapy (158).
The majority of breast cancer clinical subtypes respond well to endocrine and
targeted Her2 therapies, but due to the lack of well-defined clinical targets, TNBCs are
nonresponsive to these treatment options and consequently, chemotherapy is the standard
of care treatment (159). In order to treat TNBC more effectively, new molecular targets
need to be identified. MCP-1 represents a promising molecular target for therapeutic
intervention. MCP-1 (CCL2) is a member of the C-C chemokine family that bind to G
protein coupled receptors to regulate macrophage recruitment during wound healing,
infection, and inflammation (23). In mammary tumors, overexpression of MCP-1
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correlates with increased recruitment of macrophages and infiltration into the tumor
environment that can facilitate tumor progression through macrophage-mediated
angiogenesis (105) and through secretion of growth and survival factors (48). Recent
studies demonstrate that MCP-1 also signals to breast cancer cells to regulate survival
and invasion (111) as well as promote primary tumor growth (112). These reports
indicate that MCP-1 regulates multiple mechanisms of breast cancer progression, thus
demonstrates MCP-1 value as a potential therapeutic target. However, it’s role in TNBC
has not yet been fully elucidated.
The purpose of this study was to examine the role of MCP-1 on mammary
tumorigenesis in the triple negative C3(1)SV40Tag transgenic mouse model of breast
cancer. This was done by crossing the C3(1)SV40Tag mouse, with an MCP-1 knockout
mouse to develop an MCP-1 deficient model of mammary tumorigenesis.
C3(1)SV40Tag mice lack expression of ER, PR and Her2/neu, and the absence of these
has been associated with poor prognosis (160). The overexpression of the early region of
SV40 in the mammary epithelium induces mammary tumors in this model is due, at least
in part, to Tag inactivation of the tumor suppressors p53 and Rb. The expression of this
transgene results in the progressive development of mammary lesions that lead to
invasive carcinoma formation (161). C3(1)SV40Tag mice develop mammary epithelial
atypia at 8 wks. of age that progresses to mammary intraepithelial neoplasia (MIN) at 12
wks., which is histologically similar to human ductal carcinoma in situ (DCIS). Invasive
carcinomas usually develop at approximately 16 wks. of age. We hypothesized that
MCP-1 deficiency would reduce primary tumor initiation and tumor growth in a triple
negative mouse model of breast cancer and that this would be associated with reduced
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macrophage markers and inflammatory mediators in the mammary gland and tumor
tissue.

3.2 Materials & Methods
Animals
Female FVB/N mice were bred with male heterozygous C3(1)/SV40Tag mice (a
gift from Dr. Jeffrey Green, Chief, Transgenic Oncogenesis and Genomics Section,
Laboratory of Cancer Biology and Genetics, National Cancer Institute). The MCP1-/mice on the FVB/N background were developed in our lab. Briefly, FVB/N mice were
crossed with the C57BL/6 MCP1-/- strain, and then back-crossed an additional eight times
to derive the FVB/N MCP1-/- strain (42). Female MCP1-/- FVB/N mice were then bred
with male heterozygous C3(1)/SV40Tag MCP1-/- mice to derive the C3(1)SV40/Tag
MCP1-/- strain on the FVB/N background. Female C3(1)/SV40Tag and
C3(1)/SV40Tag/MCP-/- offspring were used in these experiments. All experimental mice
were bred and cared for in the animal research facility at the University of South
Carolina. They were housed, 2-5/cage, maintained on a 12:12-h light-dark cycle in a low
stress environment (22°C, 50% humidity, low noise) and given food and water ad
libitum. Principles of laboratory animal care were followed, and the Institutional Animal
Care and Usage Committee of the University of South Carolina approved all
experiments.
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Genotyping protocol
Female C3(1)/SV40Tag and C3(1)/SV40Tag/MCP-/- mice were used in all experiments
and were genotyped by tail snip at 3 weeks of age for the C3(1) 5’ flanking sequence and
MCP-1 gene ablation status using the primer sequences as follows:
C3(1) forward - CAG TGG TTC CCA GAG TCT CA
Tag reverse - CAG AAG CCT CCA AAG TCA GG
MCP-1 Common - TCA TTG GGA TCA TCT TGC TG
MCP-1 Wild-type - TGA CAG TCC CCA GAG TCA CA
MCP-1 Mutant - GCC AGA GGC CAC TTG TGT AG
A snip of mouse tail is added to 150ul of DirectPCR tail buffer (Viagen Biotech
Inc, Los Angeles, CA) and 2ul of Proteinase K (Viagen Biotech Inc, Los Angeles, CA)
and digested at 55°C overnight. The next day samples were incubated at 95°C for an
hour then added to a PCR cocktail for amplification. The PCR cocktail contains DNA
template, upstream and downstream primers, ddH20, and GoTaq Green Master Mix
(Promega Corp, Madison, WI). Samples were run on 2% agarose gel and compared to
control samples to determine genotype (556 base pair molecular weight for
C3(1)/SV40Tag positive samples).
Body weights and tumor palpations
Body weight was monitored weekly. C3(1)/SV40Tag mice typically develop palpable
mammary tumors between 12 and 16 weeks of age (162). Tumors were palpable
beginning at 12 weeks of age and were measured weekly by the same investigator. Upon
palpation of a tumor, calipers were used to measure the longest and shortest diameter of
the tumor. The number of tumors within each mouse was recorded and the tumor volume
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was estimated for each tumor using the formula: 0.52 X (largest diameter) X (smallest
diameter)2 as previously described (163).
Diets
The AIN-76A diet was administered to all experimental groups beginning at 4 weeks of
age (Bioserv, Frenchtown, NJ) (51). AIN-76A is a purified, balanced diet that is
phytoestrogen free. Dietary phytoestrogens have been shown to influence anxiety-related
behaviors, fat deposition, blood insulin, leptin and thyroid levels as well as lipogenesis
and lipolysis in adipocytes (164).
Tissue collection
At 23 weeks of age mice were sacrificed for tissue collection. An additional
group of mice were sacrificed at an earlier time point (12 weeks of age) for
histopathological analysis and comparison. Palpable tumors were dissected from
mammary glands and measured grossly to determine tumor volume. A portion of the
remaining thoracic mammary gland tissue was then removed from both the right and left
side. This tissue was either snap frozen in liquid nitrogen for gene expression analysis or
fixed in 4% formaldehyde for immunohistochemical analysis.
Histology
At sacrifice, a portion of mammary gland adipose tissue was excised from each
mouse, fixed overnight in 4% formaldehyde, dehydrated with 70% alcohol, and
embedded in wax. Paraffin sections were stained with hematoxylin and eosin (H&E).
The mammary gland from mice aged 12 and 23 weeks was subsequently evaluated
blindly by a pathologist and characterized according to histological alterations observed
and the grade of dysplastic changes existed as: no hyperplasia or dysplasia, atypical
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ductal hyperplasia (ADH)/mammary intraepithelial neoplasia (MIN) low grade, ductal
carcinoma in situ (DCIS)/MIN high grade, or invasive adenocarcinoma (162).
Real-time quantitative PCR
Mammary adipose tissue total RNA was extracted using Qiagen AllPrep
DNA/RNA/Protein minikit (Qiagen, Germantown, MD). Briefly, DNA was bound to
DNAEasy columns supplied by the kit and isolation was performed according to
manufacturer instructions. 100% ethanol was added to the flow through from the DNA
bound columns which contained the RNA. The RNA-containing flow through was then
bound to the RNAEasy columns supplied by the kit and centrifuged for 15s and 8000 x g.
A series of washes were performed using proprietary buffers included with the kit and the
RNA was eluted using RNA-free water. Primary tumor tissue total RNA was extracted
using TRIzol reagent (Invitrogen, Carlsbad, CA) and chloroform/isopropyl alcohol
extraction as previously described (165). Quantification of mammary adipose tissue
mRNA gene expression was performed for macrophage markers (CD64 (Fcgr1), Mertk),
cytokines (interleukin (IL)-6 (IL-6), tumor necrosis factor α (TNFα), IL-1b, IL-12, IL10), and the chemokine (MCP-1). Quantification of primary tumor mRNA gene
expression was performed for macrophage markers (CD64 and Mertk) and cytokines (IL6, TNFα, and IL1b) (Applied Biosystems, Foster City, CA) as previously described
(138). RNA quality and concentration was analyzed using a NanoPhotometer Pearl
(Implen, Westlake Village, CA). Murine 18s rRNA was used as the housekeeping gene
to normalize all of the data obtained. Quantitative reverse transcriptase polymerase chain
reaction analysis was carried out as per the manufacturer's instructions and all gene
expression primers were TaqMan Gene Expression Assays (Applied Biosystems, Foster
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City, CA). Quantification of mRNA expression of all target genes was calculated using
the 2ΔΔCT method.

Statistical analysis
All data were analyzed using commercial software (GraphPad Software, Prism 7,
La Jolla, CA, USA). A two tailed t-test was used to compare differences across groups.
Statistical significance was set with an α value of P ≤ 0.05. Data are represented as mean
± SEM.

3.3 Results
MCP-1 deficiency decreases tumor volume and tumor number in mammary primary
tumor palpations
Body weight measurements were taken weekly throughout the experimental
period to confirm normal growth patterns following deletion of MCP-1. MCP-1 ablation
did not significantly alter total body weight for the C3(1)/SV40Tag/MCP-1-/- mice when
compared to the MCP-1 sufficient mice at any point during the experiment (Figure 3.1A).
Treatment groups reported final body weight measurements of 24.25g±0.65 and
22.94g±0.90 for C3(1)/SV40Tag and C3(1)/SV40Tag/MCP-1-/- groups, respectively.
Tumor palpations began at 12 weeks of age and continued until 22 weeks of age, which
allowed us to crudely measure tumor burden between groups without anesthetizing the
animals. C3(1)/SV40Tag mice experienced significant increases in primary tumor
number beginning at 16 weeks of age (1.33±0.35 compared to 0.25±0.18 for MCP-1
deficient mice) and continued until the final week (age 22 weeks) of palpation
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measurements (4.20±0.33 compared to 1.67±0.31 for C3(1)/SV40Tag/MCP-1-/- mice)
(Figure 3.1B) (P<0.05). Both experimental groups had similar trends in primary tumor
volume growth throughout the experiment until week 22 when the C3(1)/SV40Tag mice
had a significantly large increase in tumor volume growth (1033.05±324.35mm3)
compared to the MCP-1 deficient mice (246.78±119.34mm3) (Figure 3.1C) (P<0.05).
Loss of MCP-1 results in decreased primary tumor initiation and tumor volume
Measurements taken at sacrifice for total primary tumor volume and total primary
tumor number for animals in each group indicated significant differences in
tumorigenesis with MCP-1 manipulation in this model of TNBC. MCP-1 expression
resulted in significantly increased primary mammary tumor multiplicity and growth
compared to the MCP-1 deficient group; mean tumor number/mouse (Figure 3.2A) and
mean tumor volume/mouse (Figure 3.2B) determined at necropsy were 15.86±1.07 and
3126.62±771.83 mm3 for C3(1)/SV40Tag, and 6.67±1.46 and 935.78±232.11 mm3 for
C3(1)/SV40Tag/MCP-1-/- mice, respectively (P<0.05).
Deletion of MCP-1 expression delays tumor progression in the early stages of
tumorigenesis
There was no difference in the percentage of samples classified in each
pathological stage between the groups at 23 weeks of age (Figure 3.3A). The early stage
of tumorigenesis in this model is classified as atypical ductal hyperplasia (ADH, low
grade MIN lesion), which is characterized as having more than one layer of disorganized
and atypical epithelial cells with frequent mitotic figures, lining the mammary ducts. In
the current investigation, 15.4% of C3(1)/SV40Tag and 10.0% of C3(1)/SV40Tag/MCP1-/- mice classified into this early tumorigenic stage. The next progressive level is ductal
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carcinoma in situ (DCIS, high grade MIN lesion), classified as the filling and expansion
of ducts with highly dysplastic epithelial cells confined still in the ducts without
breaching the underlying basal lamina. We report that 30.8% and 30.0% of samples for
C3(1)/SV40Tag and C3(1)/SV40Tag/MCP-1-/- mammary glands scored into this stage,
respectively. The final stage is invasive adenocarcinoma which is described as poorly
differentiated adenocarcinoma characterized by sheets of neoplastic cells occasionally
forming glandular structures separated by fine fibrovascular stroma (166). The majority
of mice in the current study were classified into this advanced stage; 53.8%
C3(1)/SV40Tag and 60% of C3(1)/SV40Tag/MCP-1-/- mice (Figure 3.3A). These
findings imply that there were no differences in the pathology between the experimental
groups at this stage of tumorigenesis. However, this may not be entirely surprising given
the advanced stage of tumorigenesis at which these analyses were performed. Therefore,
we performed an additional experiment in which the histopathology was examined at a
much earlier stage of tumorigenesis (i.e. 12 weeks of age) (Figure 3.3A). By 12 weeks of
age, this cancer model is characterized by progression into MIN/high grade (162).
Consistent with the tumor burden data, histopathology in the mammary gland of mice
sacrificed at 12 weeks of age clearly showed a delay in tumor progression for MCP-1
deficient mice compared to C3(1)/SV40Tag mice. We report that 50% of the
C3(1)/SV40Tag animals progressed into this high grade lesions (MIN, high grade), while
50% of samples were of low grade lesions (MIN, low grade); whereas, 100% of MCP-1
deficient mice remain classified into the early atypical ductal hyperplasia (ADH). Figure
3.3B-D are representative images of tumorigenesis of each histopathological stage for
this TNBC mouse model.
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MCP-1 deficiency results in a decline of macrophage markers and localized
inflammatory mediators in the mammary gland and tumor microenvironment
At 23 weeks of age, the mRNA expression of the macrophage marker, Mertk, was
significantly downregulated in the mammary gland of MCP-1 deficient mice (P<0.05),
while macrophage marker CD64 had a decreasing downtrend with P=0.06 (Figure 3.4A).
Pro-inflammatory cytokine IL-1b was significantly decreased (P<0.05), whereas, proinflammatory cytokines IL-6 and TNFa indicated a downtrend in mRNA expression in
the mammary gland with p=0.09 and p=0.06, respectively. Cytokines IL-12 and IL-10
had no change in mRNA expression in the mammary gland and, as expected, MCP-1
expression was not detected in the mammary gland of C3(1)/SV40Tag/MCP-1-/- mice,
thus confirming their knockout genotype status (Figure 3.4B).
Deletion of MCP-1 expression resulted in a significant decrease in mRNA
expression of macrophage marker CD64 in the tumor environment (P<0.05) but there
was no significant change in Mertk expression (Figure 3.4C). MCP-1 ablation also
significantly downregulated mRNA expression of the pro-inflammatory cytokine IL-6 in
the tumor environment (P<0.05); however, there was no change in TNFa and IL-1b
expression in the tumor environment (Figure 3.4D).

3.4 Discussion
Studies indicate that MCP-1 regulates multiple mechanisms of breast cancer
progression (48). Experimental evidence has shown MCP-1 to be the major chemokine
for macrophage recruitment into the tumor microenvironment (167), a process that is
known to drive tumorigenic events. However, the importance of this chemokine in the
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progression of tumorigenesis in a triple negative model of breast cancer has not been well
established. Therefore, using a gene deletion approach in the C3(1)SV40Tag mouse, we
developed a C3(1)SV40Tag/MCP-1-/- mouse to examine the effects of MCP-1 deficiency
on TNBC that is closely associated with poor prognosis in human breast cancer. Results
show that deficiency of MCP-1 reduces mammary tumorigenesis with a significant
decrease in primary tumor volume and tumor number. Consistent with the primary tumor
data, histopathology in the mammary gland of mice sacrificed at an early time point, but
well established stage for this breast cancer model, showed a delay in tumor progression
for MCP-1 deficient mice. MCP-1 deficient mice showed a reduction in mRNA
expression of macrophage markers (CD64 and Mertk) and inflammatory cytokines in the
mammary gland that are known to play a role in breast cancer progression (64, 110).
Additionally, tumor tissue gene expression of the macrophage markers CD64 and
inflammatory cytokine IL-6 were also significantly reduced in the MCP-1 deficient mice.
These data support a beneficial effect of MCP-1 deficiency on mammary tumorigenesis
in the C3(1)/SV40Tag mouse model of TNBC that is associated with a reduction in
macrophage markers and inflammatory mediators in the mammary gland and tumor
environment.
Both rodent and clinical studies have associated MCP-1 expression level with
tumorigenesis (48, 168, 169). Our results are consistent with previous studies that have
linked MCP-1 gene knockdown or ablation with a reduction in primary tumorigenesis in
various cancer models. In a study previously conducted by our laboratory, MCP-1
deficiency resulted in a reduction of overall intestinal polyp number in a mouse model of
intestinal tumorigenesis (170). Similarly, Fridlander et al., demonstrated a beneficial
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effect of MCP-1 neutralization in a murine model of non-small cell lung cancer (171).
However, there have been relatively few mechanistic studies to link MCP-1 expression to
breast cancer progression, and in particular TNBC. MCP-1 is expressed at relatively low
levels in normal mammary epithelial tissue and circulating plasma, but increases
dramatically with breast cancer progression (48, 117, 172, 173). Recently, MCP-1 has
been shown to signal to breast cancer cells to regulate survival and invasion (111),
promote primary tumor growth (112), and mediate breast cancer metastasis (174).
Interestingly, TNBC educated macrophages secrete higher amounts of MCP-1 than
macrophages co-cultured with estrogen receptor positive breast cancer (175). Most
likely, cancer cell/macrophage crosstalk in TNBC initiates a vicious circle where both
cell types reinforce each other (176, 177). MCP-1 also correlates with high tumor grade,
increased metastasis and is associated with low levels of cell differentiation and poor
prognosis in breast cancer (178). In a study previously conducted by our laboratory, we
utilized a pharmacological approach and examined the effects of an MCP-1 inhibitor on
mammary tumorigenesis in this same C3(1)SV40Tag mouse model. The chemical MCP1 inhibitor led to a significant reduction in tumor multiplicity but did not delay the initial
palpable tumor nor slow the tumor growth as tumor volume and latency were similar
between treatment groups (47). A potential limitation of that study was the long term
treatment protocol used as the inhibitor was given in the food for a period of 16 weeks.
Thus, it is possible that the animals developed a tolerance to the inhibitor treatment as a
decrease in circulating levels of MCP-1 in plasma was not observed. This suggests that
the overall effectiveness of the treatment dose, timing and administration method may not
have been optimal in this animal model. Given the promising results of MCP-1
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inhibition, but also considering the limitations of that study, we developed the MCP-1
global knockout C3(1)SV40Tag mouse to more conclusively examine the role of MCP-1
on TNBC. In the present investigation, we show for the first time that genetic
knockdown of MCP-1 expression can lead to a significant reduction in mammary tumor
volume and multiplicity in the C3(1)SV40Tag transgenic mouse model of TNBC.
Macrophages play a key role in tumorigenesis; they are a major player in the
inflammatory response that contributes to cellular proliferation, transformation,
promotion, invasion, angiogenesis, apoptosis and metastasis (106, 179). Given that
MCP-1 has been implicated as the most important chemokine for macrophage
recruitment into the tumor microenvironment, we next examined the effect of MCP-1
deficiency on select macrophage markers in the mammary tissue and tumor
microenvironment. In the past several years, considerable progress has been made in
distinguishing macrophages from dendritic cells, two immune cells of similar origin
reflected by overlapping functions and molecular profiles. More recently, two mRNA
transcripts that are unique to macrophages and not dendritic cells have been identified;
Mer tyrosine kinase receptor (Mertk), which is involved in the phagocytosis of apoptotic
cells, and Fcgr1, which encodes the immunoglobulin receptor CD64 on macrophages
(180). Studies have implicated Mertk to not only be highly elevated in human breast
carcinoma samples, but also mediate efferocytosis in macrophages and advance tumor
progression through the inhibition of immune checkpoints (181). In this experiment,
MCP-1 depletion resulted in a reduction in both Mertk and CD64 mRNA expression in
the mammary gland, and also CD64 mRNA expression in the tumor tissue. These results
are consistent with a very recent study in which Fang et al., demonstrated a reduction in
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the recruitment of macrophages to the tumor microenvironment with targeted MCP-1
gene silencing in a model of TNBC cancer (112). Similarly, previous work by our group
has shown equivalent results using pharmacological inhibition of MCP-1 in TNBC (47).
These findings should be substantiated through the use of cell sorting to solidly establish
the role of MCP-1 depletion on macrophage infiltration and specific macrophage
phenotypes that may be associated with TNBC.
Studies have established that the mutual interaction of macrophages with cancer
cells enhances survival, invasion, promotes primary tumor growth and increases the
production of inflammatory cytokines to transform the tumor microenvironment so that it
favors tumorigenesis (111, 112). The inflammatory cytokines TNFa, IL-1b, and IL-6
have been associated with poor prognosis and increasing risks of metastasis in breast
cancer in addition to being related to tumor macrophage expression of MCP-1 (48, 110).
We investigated the expression of these inflammatory cytokines in the surrounding
dysplastic mammary tissue and in the tumor environment. Our findings indicate that the
absence of MCP-1 expression significantly corresponds with decreases in mRNA
expression of TNFa, IL-1b, and IL-6 in the mammary gland and decreases in IL-6
expression in the tumor. These data are supported in a study by Ueno et al, that
demonstrated MCP-1 expression levels are associated with IL-6 expression levels in
human breast cancer tissues (48). There is consistent data showing increased levels of
IL-6 in breast cancer patients when compared to healthy controls and increased levels of
IL-6 have also been correlated with clinical tumor stage, lymph node infiltration and
recurrent disease (182). IL-6 levels have also been associated with poor prognosis for
time-to-progression and death in advanced stage patients (183).
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In summary, we report for the first time that ablation of MCP-1 expression
through genetic deletion results in decreased mammary tumorigenesis and downregulated
localized inflammation in the C3(1)/SV40Tag model of TNBC. Although, MCP-1
expression has been connected with regulating multiple mechanisms of breast cancer
progression, its involvement in tumorigenesis in a TNBC model has not been fully
established. MCP-1 provides a direct link between inflammation and macrophage
recruitment and not surprisingly, therefore has an emergent role in the etiopathogenesis
of breast cancer. Given the profound clinical implications, more research is needed to
fully elucidate the role of this chemokine in breast cancer progression so that targeted
therapies can be developed.
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3.5 Figures & Legends

Figure 3.1:
Body weight characteristics and tumor palpations. A. Body weight in grams. B. Tumor
number palpations. C. Tumor volume palpations. *P<0.05. Data are represented as ±
SEM, C3(1)/SV40Tag n=15, C3(1)/SV40Tag/MCP-1-/- n=12.
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Figure 3.2:
Tumor statistics at necropsy. A. Total tumor number per mouse taken at necropsy. B.
Total tumor volume per mouse taken at necropsy. *P<0.05. Data are represented as ±
SEM, C3(1)/SV40Tag n=15, C3(1)/SV40Tag/MCP-1-/- n=12.
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Figure 3.3:
Mammary gland histopathology for each treatment group. A. Graph of mammary gland
pathology score for mice at 12 weeks and 23 weeks of age for both groups. B.
Representative images of atypical ductal hyperplasia (ADH, low grade MIN lesion)
characterized by several layers of disarranged atypical epithelial cells with frequent
mitotic figures. C. Representative images of ductal carcinoma in situ (DCIS, high grade
MIN lesion) characterized by filling and expansion of ducts with dysplastic epithelial
cells without breach of the basement membrane or invasion of the surrounding adipose
tissue. D. Representative images of invasive adenocarcinoma characterized by
pleomorphic neoplastic cells arranged in sheets or in tubules separated by fine
fibrovascular stroma. Figures B-D shown at 10x magnification. Data are represented as
percentage of total samples for each time point/group, 12-week time point: C3(1)/SV40Tag
n=6, C3(1)/SV40Tag/MCP-1-/- n=5, 23-week time point: C3(1)/SV40Tag n=15,
C3(1)/SV40Tag/MCP-1-/- n=12.
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Figure 3.4:
Macrophage markers and localized inflammation in the mammary gland and tumor. A.
Relative gene expression of macrophage markers in the mammary gland. B. Relative
gene expression of inflammatory mediators in the mammary gland. C3(1)/SV40Tag
n=10, C3(1)/SV40Tag/MCP-1-/- n=7. C. Relative gene expression of macrophage markers
in the tumor. D. Relative gene expression of inflammatory mediators in the tumor.
*P£0.05. Data are represented as ± SEM, C3(1)/SV40Tag n=13, C3(1)/SV40Tag/MCP-1-/n=10.

61	
  

	
  

CHAPTER 4
EFFECTS OF HIGH FAT DIET-INDUCED OBESITY ON MAMMARY
TUMORIGENESIS IN THE PYMT/MMTV MURINE MODEL1

1

	
  Cranford TL, Velazquez KT, Enos RT, Bader J, Carson MS, Fan D, Bellone RR,
Chatzistamou I, Nagarkatti M, Murphy EA. Effects of high fat diet-induced obesity on
mammary tumorigenesis in the PyMT/MMTV murine model (Manuscript in
Preparation)
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Abstract
Clinical studies provide strong evidence that obesity and associated adipose tissue
inflammation are risk factors breast cancer; however, mechanistic knowledge of the
interaction of obesity, breast cancer and menopausal status has proven to be not only
lacking, but contradictory. Obesity-induced inflammation and elevated biosynthesis of
estrogens, through aromatase-mediated metabolism of precursors, have been linked with
hormone receptor positive (HP) postmenopausal breast cancer but not previously
associated with premenopausal breast cancer risk. Thus, further delineation of the
interaction of obesity, inflammation, and aromatase is required for the development of
therapeutic treatment options. The purpose of this study was to examine the effect of
high fat diet (HFD)-induced inflammation on tumorigenesis in a model of pre and
postmenopausal HP breast cancer. Female PyMT/MMTV ovary intact and
ovariectomized mice were fed low and HFD diets to examine the role of obesity-induced
inflammation and hormone production in the development of HP breast cancer. Tumor
statistics for number, volume, weight, histopathology scoring and gene expression of
macrophage and inflammatory mediators were measured in the adipose tissue and
mammary gland at sacrifice. HFD feedings of ovary intact mice resulted in increased
adiposity and tumorigenesis, indicated by increased primary tumor volume, multiplicity,
tumor burden, and increased tumor progression represented by histopathological scoring.
HFD-induced obesity significantly upregulated aromatase and macrophage marker
expression in the adipose tissue (F4/80 and CD11c) and mammary gland (Mertk) in a
premenopausal model of breast cancer. Conversely, HFD feedings had no significant
effect on tumorigenesis in a postmenopausal model of breast cancer despite large
increases in adiposity in ovariectomized mice. This data suggests that obesity-induced
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increases in inflammation and hormone production, via aromatase expression, is
associated with increases in tumorigenesis in a model of premenopausal HP breast cancer
in the PyMT/MMTV strain.

4.1 Introduction
The etiopathogenesis of breast cancer is elaborate and involves the interaction of genetic
and environmental factors. Epidemiological studies provide strong evidence to suggest
that obesity is a risk factor for breast cancer. However, inconsistencies in the literature
imply that the complexity of the relationship between breast cancer and obesity remains
inadequately understood. In the case of younger women, the link between body mass and
breast cancer risk is controversial. Some clinical studies report a null or inverse
association between obesity and breast cancer risk (69-72), a few epidemiological studies
suggest reduced overall risk of premenopausal breast cancer associated with obesity
(184), while other investigators report weight gain and central obesity increase the risk of
premenopausal breast cancer (73-77). In postmenopausal women the relationship is
clearer; the majority of evidence supports a direct link between obesity and the risk for
certain clinical subtypes of breast cancer (78-81). For instance, cohort and case control
studies indicate that obesity is an independent risk factor for postmenopausal estrogen
receptor positive (ER+) and progesterone receptor positive (PR+) breast cancer (80, 81,
84, 86, 89, 185) and experimental studies in mice substantiate these claims (81, 186-189).
Women with the greatest increase in weight have higher risk at older ages and this
association appears to be stronger for HP tumors (190). Given that two out of three
women in the United States are overweight or obese, an understanding of the mechanisms
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that link obesity to breast cancer, and the connection with menopausal status, is of critical
public health importance.
A number of mechanisms are likely to link obesity to breast cancer. However,
inflammation is arguably at the forefront. Chronic inflammation is recognized as an
important mediator in the clinical and biochemical complications associated with obesity
and also breast tumor biology and causation. Inflammation in adipose tissue, with
infiltration by macrophages, is a well-established characteristic of obesity and its
presence in the breast creates local conditions that favor breast epithelial cell
transformation, cancer cell proliferation and invasion, as well as, tumor-related
neovascularization, that contribute to poor prognosis. Further, obesity-mediated
inflammation has been reported to drive estrogen synthesis, which increases the risk of
HP breast cancer; previous studies have linked the upregulation of adipose tissue proinflammatory cytokines with the expression of the estrogen synthase cytochrome P450
(aromatase) in murine (97) in both pre and postmenopausal human breast cancer (68, 98).
The purpose of this study was to examine mammary tumorigenesis in response to
HFD feedings in the PyMT transgenic murine model of tumorigenesis. The
PyMT/MMTV is an experimental model that presents morphological similarities with
human breast carcinoma. In this model, the expression of the oncoprotein, polyoma virus
middle T antigen, is under the control of the mouse mammary tumor virus promoter and
is therefore restricted to the mammary epithelium (191). In addition to the tumor
progression similarities, the expression of biomarkers in PyMT-induced tumors, to
include the loss of ER+ and PR+ receptors and overexpression of ErbB2/Neu/HER2 as
the cancer progresses to malignancy, is also consistent with those associated with poor
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outcome in human breast cancer. While the majority of studies investigating the
relationship between HFD-induced obesity and mammary tumorigenesis have been
performed in the FVB/N background, a strain traditionally shown to be HFD-induced
obesity resistant, we utilized the C57Bl/6 background, a strain that is more susceptible to
HFD-induced obesity. Further, by utilizing both intact and ovariectomized mice, we
were able to evaluate the effects of HFD feedings in a model of pre and postmenopausal
breast cancer. Given that inflammation is a likely link between obesity and breast cancer,
we further examined changes in inflammatory-related parameters in association with the
tumorigenic outcomes.

4.2 Materials & Methods
Animals
Male PyMT/MMTV mice on a C57Bl/6 background were randomly bred with
female wild-type (WT) mice to obtain female mice heterozygous for the PyMT
transgene. Two independent experiments were conducted to examine mammary
tumorigenesis as it pertains to menopausal status. The first experiment (Exp1) utilized
PyMT ovary intact females and female WT littermates were included as a non-disease
control. Mice in Exp1 were sacrificed at 20 weeks of age (16 weeks of diet treatment).
The second experiment (Exp2) only included PyMT ovariectomized females. At 5 weeks
of age, mice underwent ovariectomy surgery and were allowed one week to recover prior
to the start of diet treatments. Mice in Exp2 were sacrificed at 24 weeks of age (18
weeks of diet treatment). All experimental mice were bred and cared for in the animal
research facility at the University of South Carolina. They were housed, 3-5/cage,
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maintained on a 12:12-h light-dark cycle in a low stress environment (22°C, 50%
humidity, low noise) and given food and water ad libitum. Principles of laboratory
animal care were followed, and the Institutional Animal Care and Usage Committee of
the University of South Carolina approved all experiments.
Ovariectomy surgery
Mice are briefly anesthetized with isoflurane. The dorsal mid-lumbar area was shaved
and swabbed with iodine and alcohol. A 2cm dorsal midline skin incision was made
halfway between the caudal edge of the ribcage and the base of the tail. The fascia was
cleared away using blunt dissection. A single incision of less than 1cm long was made
into the muscle wall on both the right and left sides approximately 1cm lateral to the
spine. The ovary and the uterine horns located in the fat pad under the dorsal muscle
were extracted through the incisions with forceps. Both uterine horns were tied beneath
the ovary with a suture (non-absorbable suture 5-0, cat # S-G518R13) and ovaries were
removed with single cuts. The uterine horns were placed back into the peritoneal cavity.
Muscle incisions were closed with 5-0 absorbable suture (Cat # S-G518R13-U). Wound
clips were used to close skin incision. Animals were examined for incision repair or
infection for at least 72 hours post-surgery. Wound clips were removed at 7-day postsurgery.
Genotyping protocol
Female mice were used in all experiments and were genotyped for the PyMT
transgene using the primer sequences as follows:
PYVT-1 GGAAGCAAGTACTTCACAAGGG,
PYVT-2 GGAAAGTCACTAGGAGCAGGG.
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A snip of mouse tail is added to 150ul of DirectPCR tail buffer (Viagen Biotech
Inc, Los Angeles, CA) and 2ul of Proteinase K (Viagen Biotech Inc, Los Angeles, CA)
and digested at 55°C overnight. The next day samples were incubated at 95°C for an
hour then added to a PCR cocktail for amplification. The PCR cocktail contains DNA
template, upstream and downstream primers, ddH20, and GoTaq Green Master Mix
(Promega Corp, Madison, WI). Samples were run on 2% agarose gel and compared to
control samples to determine genotype (520 base pair molecular weight for
PyMT/MMTV positive samples).
Diets
For Exp1, PyMT mice and WT non-disease control mice were randomly assigned
to either a low fat diet (LFD) or a HFD treatment group beginning at 4 weeks of age. The
AIN-76A diet (11.5% kcal as fat) was used for the LFD (Bioserv, Frenchtown, NJ) (51,
133). AIN-76A is a purified, balanced diet that is phytoestrogen free. Dietary
phytoestrogens have been shown to influence anxiety-related behaviors, fat deposition,
blood insulin, leptin and thyroid levels as well as lipogenesis and lipolysis in adipocytes
(164). The D12492 diet (60% kcal as fat) was used for the HFD (Research Diets, New
Brunswick, NJ). Mice were fed their respective diets for 16 weeks.
In Exp2, PyMT mice at 6 weeks of age were randomly assigned to the same LFD
and HFD-treatment groups used in experiment 1. Mice were fed their respective diets for
18 weeks.
Body weights, food intake, and body composition
Body weight and food intake were monitored weekly for both experiments. Body
composition for WT mice was assessed at the conclusion of the study (20 weeks of age)
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in Exp1. PyMT groups were not analyzed for body composition as the tumors can alter
lean mass calculations. Briefly, mice were placed under anesthesia (isoflurane
inhalation) and were assessed for lean mass, fat mass, and body fat percentage via dualenergy x-ray absorptiometry (DEXA) (Lunar PIXImus, Madison, WI) (51).
Tumor palpations
Tumors were palpable beginning at 14 weeks of age (10 weeks of diet treatment)
and 14 weeks of age (8 weeks of diet treatment) for each of Exp1 and Exp2, respectively,
by the same investigator. PyMT/MMTV mice typically develop palpable mammary
tumors between 12 and 16 weeks of age (191) . Upon palpation of a tumor, calipers were
used to measure the longest and shortest diameter of the tumor. The number of tumors
within each mouse was recorded and the tumor volume was estimated for each tumor
using the formula: 0.52 X (largest diameter) X (smallest diameter)2 as previously
described (163).
Tissue collection
Following 16 weeks (Exp1) and 18 weeks (Exp2) of dietary treatment, mice were
sacrificed for tissue collection. Visible tumors were dissected from mammary glands and
measured to determine tumor weight and tumor volume. A portion of remaining thoracic
mammary gland tissue was then removed from both the right and left side. Visceral fat
pads were removed. These tissues were either snap frozen in liquid nitrogen for gene
expression analysis or fixed in 4% formaldehyde for immunohistochemical analysis.
Histology
A portion of the thoracic mammary gland from both Exp1 and Exp2 was excised
from each mouse, fixed overnight in 4% formaldehyde, dehydrated with alcohol, and
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embedded in wax. Paraffin sections were stained with hematoxylin and eosin (H&E).
The mammary gland was subsequently evaluated blindly by a pathologist and
characterized according to the grade of dysplasia: no hyperplasia, adenoma/mammary
intraepithelial neoplasia (MIN), and early and late invasive carcinoma for both
experiments (191).
PCR cleanup for sequencing of PyMT transgene
PyMT transgene was sequenced to design qPCR primers for verification that diet did not
affect transgene expression. One gDNA sample and a cDNA sample from each treatment
groups (PyMT Con 4 and PyMT HFD 2) were used for sequencing experiments of the
PyMT transgene. gDNA and cDNA were both included to confirm that the transgenic
sequence does not contain intron insertions that could interfere with gene expression
results. PCR cleanup of samples was performed using EdgeBio Quick Step 2 PCR
purification kit following the manufactures protocol (Edge Biosystems, Gaithersburg,
MD). Eluates were retained for sequencing.
Sequencing of PyMT transgene
Two Sanger sequencing reactions (one for each primer) were performed for the three
samples using Big Dye chemistry (Applied Biosystems, Foster City, CA) following
manufacturer’s recommendations unless otherwise noted. Specifically, each 20 µL
reaction contained 1.0ul of Big Dye version 3.1, 0.5ul of primer (10 mM of either
PYVT1 or PYVT2) and 5ul of PCR cleaned product. Chain termination PCR was
performed for 50 cycles. Products were purified of excess primers and dNTPS using
Edge Bio Performa Gel Filtration Cartridge (Edge Biosystems, Gaithersburg, MD) and
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detected using an Applied Biosystem 3730 DNA Analyzer (Applied Biosystems, Foster
City, CA). Sequences were visualized and assembled using the Sequencher Version 5.2.4
(http://www.genecodes.com). Genomic and cDNA sequences aligned as expected and
these sequence data were utilized to design RT-qPCR primers.
Real-time quantitative PCR
Gonadal adipose tissue and mammary gland was homogenized under liquid
nitrogen using a polytron, and total RNA was extracted using chloroform and the
E.Z.N.A. Total RNA Kit II (Omega Bio-tek, Norcross, GA) (192). Quantification of
gonadal adipose tissue mRNA gene expression for macrophage markers (F4/80 and
CD11c) and the adrenal enzyme Cyp19A1 (aromatase), mammary gland mRNA
expression of macrophage markers (F4/80, CD11c and Mertk), inflammatory markers
(MCP-1, IL-6, and TNFα), markers of angiogenesis (Vegfα, MMP2 and MMP9), and
proliferation (Ki67) were performed as previously described (Applied Biosystems, Foster
City, CA) (138). Quantification of mammary gland expression of the PyMT transgene
was performed using a custom designed assay with forward primer:
GGGCGGGTCTGAGTCCAT, reverse primer: AAATGAGCCCTCTGCAAATCC, and
fluorescent probe: GGGAGGGTCTGATTCTTCG. Primers designed using the program
Primer Express 3.0.1 (Applied Biosystems, Foster City, CA). Murine 18s rRNA was
used as the housekeeping gene to normalize all of the data obtained. Quantitative reverse
transcriptase polymerase chain reaction analysis was carried out as per the manufacturer's
instructions and all primers used were TaqMan Gene Expression Assays (Applied
Biosystems, Foster City, CA). Quantification of mRNA expression of all target genes
was calculated using the 2ΔΔCT method.
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Statistical analysis
All data were analyzed using commercial software (GraphPad Software, Prism 7,
La Jolla, CA, USA). For Exp1, total body weight was analyzed using a two-way analysis
of variance at each time point. Total visceral fat weight, total gonadal fat weight, mRNA
analysis of gonadal fat F4/80, mammary gland inflammation and proliferation mediators
and VEGFa were analyzed using a two-way analysis of variance. All DEXA
information, sacrifice tumor data, mRNA analysis of gonadal fat CD11c, CD64, Cy19A1,
mammary gland mRNA analysis of MMP2/9 were analyzed using a two tailed t-test.
Bonferroni correction was used for all post-hoc analyses. In Exp2, all data was analyzed
using a two tailed t-test. Statistical significance was set with an α value of P ≤ 0.05.
Data are represented as mean ± SEM.

4.3 Results
PyMT and wild-type mice fed a HFD have increased body weight gain and larger total
visceral fat pad weight than mice fed a LFD
The HFD treatment significantly increased body weight for both the WT and PyMT
groups beginning at 8 weeks of diet treatment and remained elevated through the 16week treatment period (Figure 4.1A, P<0.05). A similar main effect of diet was observed
for the total absolute weight of the visceral fat pads, with the HFD-fed mice having
significantly greater total weight (Figure 4.1B, P<0.05). There was no difference
between the HFD-treated groups for bodyweight (Figure 4.1A) and total visceral fat pad
weight (Figure 4.1B). Body composition analysis for the WT mice at week 16 of
treatment indicated that the mice fed the HFD had significantly greater body fat weight in
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grams and body fat percentage (Figure 4.1C, D) with no difference for lean mass in
grams between diet treatment groups (Figure 4.1E, P<0.05).

Chronic consumption of a HFD diet increases tumorigenesis and histopathological tumor
stage progression in a premenopausal model
Chronic consumption of a HFD significantly increased primary mammary tumor growth
and multiplicity with the mean tumor volume/mouse (Figure 4.2A) and mean tumor
number/mouse (Figure 4.2B) determined at necropsy to be 1989±380 mm3 and 8.85±0.96
for LFD, and 3163±542 mm3 and 10.47±0.76 for HFD mice, respectively (P<0.05). HFD
consumption significantly increased tumor burden (i.e. weight) (Figure 4.2C) with the
mean/mouse to be 1599.7±206.9mg for LFD and 2554.0±375.4mg for HFD (P<0.05).
Tumorigenesis in this model is classified into 4 distinct stages. Hyperplasia, the earliest
change in the mammary gland, is characterized by clusters of densely packed lobules
formed on the duct called the hyperplastic lesion. This change occurs around 4-6 weeks
of age in this model and considering the age of the mice at sacrifice, it is understandable
why we reported no samples in this early stage (Figure 4.2D). The next progressive stage
is MIN (mammary intraepithelial neoplasia)/adenoma and describes a more florid
epithelial proliferation still confined to the basement membrane of the duct, with minimal
cytological atypia and no evidence of invasion or metastasis. In the current investigation,
40% of the samples classified in the low grade MIN/adenoma stage in the LFD-fed mice
while zero mice from the HFD treated animals scored into this grade (Figure 4.2D).
Progressively more advanced and considered the initial stage of malignant transition is
the Early Carcinoma classification characterized by great cytological atypia and the
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identification of early stromal invasion. The tumor cells now appear pleomorphic,
showing moderate variation in nuclear morphology, size and shape and the majority of
ducts are still morphologically normal, except for focal areas in which there is mild
ductal epithelial hyperplasia with a small increase in the number of cell layers. We report
no difference between the percentage of animals from each group that scored into this
Early Invasive Carcinogenesis (40% for each group) stage (Figure 4.2D). Late
Carcinoma is classified as poorly differentiated invasive ductal carcinoma. Tissues are
composed of solid sheets of epithelial cells with little to no remaining acinar structures
visible. The malignant cells in the tumor have marked variation in cellular and nuclear
size and shape with vesicular nuclei and prominent nucleoli. We report 20% of the LFDtreated animals progressed to Late Carcinoma, however, 60% of the HFD treated mice
classified into this advanced invasive carcinoma stage, (Figure 4.2D). Figure 4.2E
illustrates a representative H/E stained sample from the LFD/Early Invasive and a
HFD/Late Advanced Invasive stages. Given that tumorigenesis in this murine PyMT
model is initially driven by the expression of the polyoma virus middle T oncoprotein, we
wanted to establish that the expression of the transgene itself is not affected by diet
manipulation, thus resulting in increased tumorigenesis due to differences in transgene
expression. In this current experiment, diet treatment does not alter expression levels of
the transgene as both experiment groups report similar mRNA expression levels (Figure
4.2F).
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HFD intake leads to expansion of gonadal fat pad weight and increases aromatase
expression and macrophage infiltration into the adipose tissue regardless of genotype
A significant main effect of diet was observed in the gonadal fat pad of the HFD-treated
groups (Figure 4.3A, P<0.05). Cytochrome p50 aromatase (CyP19) mRNA expression
was significantly elevated in the gonadal adipose tissue of the HFD-fed mice compared to
the LFD-fed mice (Figure 4.3B, P<0.05). A significant main effect of diet was observed
for macrophage markers F4/80 and CD11c expression in the adipose tissue (Figure 4.3C,
P<0.05).
Tumorigenesis increases inflammatory and proliferation markers in the mammary gland
There was no difference in the mRNA expression of macrophage markers (F4/80
and CD64) between the LFD and HFD cancer groups in the mammary gland. However,
HFD-feedings resulted in an upward trend in the expression of the macrophage marker
Mertk in the mammary gland (Figure 4.3D, p=0.06). A significant genotype effect was
observed in the mRNA expression of inflammatory cytokine and chemokine markers (IL6, TNFα, and MCP-1), and the proliferation marker Ki67 of the mammary gland (Figure
4.3E, P<0.05). A main effect of both diet and genotype was observed for the angiogenic
marker Vegfα. No significant difference in the gene expression of the matrix
metalloproteinases (MMP2 and MMP9) was observed between cancer groups in the
mammary gland (P<0.05) (Figure 4.3F).
Long-term HFD feedings drastically increases bodyweight gain for ovariectomized mice
resulting in significant increases in total visceral fat weights over LFD-fed mice
The HFD treatment significantly (over 2 fold) increased body weight for ovariectomized
mice beginning with the first week of diet treatment and remained elevated through the

75	
  

	
  

18-week treatment period (Figure 4.4A, P<0.05). A similar main effect of diet was
observed for the total absolute weight of the visceral fat pads (3 fold), with the HFD-fed
mice having significantly greater total weight (Figure 4.4B, P<0.05).
Diet treatments had no effect on tumorigenesis in ovariectomized mice
HFD-induced obesity resulted in no significant change in tumor volume (Figure 4.5A),
tumor number (Figure 4.5B), nor tumor weight (Figure 4.5C) between diet treatment
groups. In fact, only a small percentage of mice from each group, 25% and 20% for LFD
and HFD-fed mice from each group respectively, reported histopathological mammary
gland stage progression into the MIN grade or beyond (Figure 4.5D). This is surprising
given the analysis was performed at 24 weeks of age, an age well characterized into
MIN/late advanced adenocarcinoma (191).
4.4 Discussion
Breast carcinomas continue to be the most commonly occurring cancer in women
and the second leading cause of cancer-related deaths. Multiple molecular changes
arising as a consequence of increased amounts of body fat are likely to contribute to the
rising incidence of breast cancer and worse outcomes in the obese population; however,
the exact mechanisms driving this relationship have not yet been fully elucidated. We
examined mammary tumorigenesis in response to HFD feedings in the PyMT/MMTV
transgenic murine model of tumorigenesis, an experimental model that presents
morphological similarities with human breast carcinoma. This was done using both
ovary-intact and ovariectomized mice in order to examine the influence of menopausal
status on this response. Results show that ovary-intact mice fed a HFD not only have
large increases in body weight gain and absolute visceral fat pad weight, but also have
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significant proneoplastic effects on tumorigenesis as demonstrated by increases in
primary tumor volume, tumor multiplicity, and total primary tumor burden (i.e. weight).
Consistent with the tumor data, histopathology in the mammary gland of ovary-intact
mice show an increase in histopathological stage progression with HFD-induced obesity.
HFD treatment of intact mice also led to significant increases in aromatase and
macrophage marker (F4/80 and CD11c) mRNA expression in the gonadal adipose tissue
and an increasing trend of the macrophage cell marker Mertk expression in the mammary
gland. However, we report no significant difference between diet treatment groups for
localized inflammatory mediator mRNA expression, suggesting that localized
inflammation in the mammary gland is not responsible for driving the HFD-induced
increases in tumorigenesis seen in this model. HFD treatment in ovariectomized PyMT
mice results in large increases in adiposity but has no significant effect on tumorigenesis,
contrary to what we report in the ovary-intact mice. These data provide evidence that
HFD-induced obesity exacerbates tumorigenesis in the HP PyMT/MMTV breast cancer
model, which is associated with increases in aromatase. However, this response appears
to be differentially dependent on menopausal status.
Breast cancer is a uniquely heterogeneous disease with different biological and
clinical patterns between younger and older women. Thus, menopausal status as a
prognostic factor becomes a topic of scrutiny. Differential associations have been
identified according to menopausal status as there is clear evidence to support an
increased breast cancer risk as a function of increasing BMI in postmenopausal women
(78-95); however, studies in premenopausal women are more controversial. Our results
are consistent with previous epidemiological studies, such as Chang et al., that have
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reported that obesity is significantly associated with increasing risk of breast cancer in a
patient population that were more likely to be premenopausal (76). Similarly, Nagrani et
al., concluded that central obesity is a risk factor for breast cancer irrespective of
menopausal status (73). However, relatively few mechanistic studies investigating
obesity and breast cancer progression in premenopausal animal models have been
performed. Contradictory to published studies that have determined a positive correlation
between obesity and breast cancer risk in a postmenopausal model, our data demonstrates
no significant effect of HFD-induced obesity on breast cancer progression in this murine
model. This is surprising considering there is overwhelming data to suggest that obese
postmenopausal women are at significantly increased risk of developing HP breast
cancer. With obesity, ER+ and PR+ hormone-dependent breast cancers are of
importance as estrogen signaling is likely to be a key contributor to obesity-associated
breast cancer. Importantly, activation of ERa-dependent gene expression as a
consequence of adipose inflammation has been observed in murine mammary fat pads
and human breast samples (68, 97, 98).
The primary site for estrogen biosynthesis in premenopausal women is the ovary
but other peripheral sources have increased relative importance in estrogen synthesis.
For instance, adipose tissue expresses the estrogen synthase cytochrome aromatase p450
(100, 101), which is encoded by the Cyp19 gene, and contributes to estrogen synthesis.
In postmenopausal women, obesity and associated inflammation have been shown to
contribute to increased breast cancer risk as the adipose tissue is the primary source of
estrogen synthesis due to increased aromatase expression (102-104). In support of this
concept, studies link aromatase expression in inflamed adipose tissue of obese women
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with the upregulation of proinflammatory mediators, such as macrophages, as aromatase
transcription can be induced by the interaction of inflammatory cytokines with their
receptors. Our data is consistent with this concept in that ovary-intact mice fed a HFD
have significant increases in aromatase expression in the gonadal adipose tissue. We
show that increased aromatase expression is associated with increases in certain
macrophage markers and increases in not only primary tumor growth but also
histopathological grade of the mammary gland in obesity-induced ovary-intact mice.
Thus, it is likely that paracrine interactions between macrophages and other cell types
operate on an inflammatory axis that results in elevated estrogen biosynthesis and
expression; however, further delineation of this axis is required before treatment
mechanisms can be established.
There are several limitations to our study pertaining to the ovariectomized
postmenopausal model that warrant cautious interpretations of the findings. We designed
this study to replicate a mouse model where we could exclusively look at the role of
adipose tissue aromatase expression on mammary tumor initiation and progression
without the effect of endogenous estrogen and progesterone. However, tumorigenesis in
this model appears to be highly dependent on these endogenous hormones and removing
the ovaries at 5 weeks of age may have interfered with tumor initiation in these mice,
thus the relatively low tumor number in the ovariectomized versus the ovary intact mice.
Another potential limitation is the effect that the removal of the ovaries had on normal
mammary gland development. Literature suggests that estrogen is circulating in female
mice at 4 weeks of age but progesterone is not bioavailable until 7 weeks of age or even
sexual maturation which occurs around 8 weeks of age. Bocchinfuso et al., demonstrated
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that without functioning estrogen and progesterone, normal mammary gland development
does not occur (193). Given that we ovariectomized these mice at 5 weeks of age, we
cannot establish that decreases in tumor initiation in the ovariectomized mice was due to
decreases in bioavailable estrogen or immature mammary gland development. For future
studies, it may be beneficial to wait to remove the ovaries until sexual maturation occurs.
However, it should be noted that by this time point this mouse model would have
progressed into the MIN histopathological tumor stage; thus, analysis of obesity-induced
pathologies would be on tumor progression rather than tumor initiation. Given, the
amount of time it takes for increased adiposity to occur in a HFD-induced obesity model,
this represents a challenge as this transgenic model produces tumorigenesis in a relatively
short time frame.
In summary, we report that HFD-induced obesity results in increases in mammary
tumorigenesis and upregulated aromatase expression in the gonadal adipose tissue in the
HP PyMT/MMTV murine model of premenopausal breast cancer. Although, aromatase
expression has been implicated in modulating multiple mechanisms in postmenopausal
breast cancer, its involvement in tumorigenesis in a premenopausal model has not been
established. While it is well known that obesity leads to increased levels of
proinflammatory mediators, further research is required to demonstrate the functional
link of increased aromatase expression in mammary tumorigenesis. This newly
discovered obesity, inflammation, and aromatase axis provides the basis for developing
mechanism-based strategies to reduce the risk of HP breast cancer in this growing
segment of the population.
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4.5 Figures & Legends

Figure 4.1:
Body weight characteristics for Exp1. A. Body weight in grams. B. Total absolute weight of
visceral fat pads. C. Body composition analysis of WT mice, Body fat in grams. D. Body fat
percentage. E. Lean weight in grams. *main effect of diet. Data are represented as ± SEM,
n=7 WT LFD, n=8 WT HFD, n=8 PyMT LFD, n=12 PyMT HFD, n=15.
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Figure 4.2:
Sacrifice tumor and histopathology scoring for Exp1. A. Sacrifice tumor volume per
mouse. B. Sacrifice tumor number per mouse. C. Sacrifice tumor burden (weight) per
mouse. D. Mammary gland histopathology scoring for both treatment groups. E.
Representative images from each treatment group of the most frequently reported stage in
each group. F. mRNA expression of the PyMT transgene in the mammary gland.
*P<0.05. Data are represented as ± SEM, PyMT LFD, n=12 PyMT HFD, n=15.
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Figure 4.3
Markers of inflammation in the gonadal fat and mammary gland. A. Total gonadal fat
weights for each treatment group. B. Aromatase mRNA gene expression for cancer
groups in the gonadal fat. C. mRNA expression of macrophage marker F4/80 and CD11c
in gonadal fat. D. mRNA expression of macrophage marker F4/80, CD11c, Mertk in
mammary gland. E. Markers of inflammation and proliferation in the mammary gland to
include MCP-1, IL-6, TNFa, Ki67. F. Markers of neovascularization in the mammary
gland to include Vegfa, MMP2/9. *main effect of diet, #main effect of genotype. Data are
represented as ± SEM, WT LFD, n=8 WT HFD, n=8 PyMT LFD, n=12 PyMT HFD, n=15.

83	
  

	
  

Figure 4.4
Bodyweight characteristics for Exp2. A. Body weight in grams. B. Total absolute visceral
fat pad weight. *P<0.05. Data are represented as ± SEM, PyMT OVX LFD, n=9 PyMT
OVX HFD, n=12.
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Figure 4.5:
Sacrifice tumor and histopathology scoring for Exp2. A. Sacrifice tumor volume per
mouse. B. Sacrifice tumor number per mouse. C. Sacrifice tumor burden (weight) per
mouse. D. Mammary gland histopathology scoring for both treatment groups. *P<0.05.
Data are represented as ± SEM, PyMT OVX LFD, n=9 PyMT OVX HFD, n=12.
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CHAPTER 5
SUMMARY AND CONCLUSIONS
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Obesity is now considered to be a modern epidemic and its strong association
with insulin resistance and chronic inflammation has elicited interest in the underlying
mechanisms of these pathologies. Adipose tissue inflammation is causally associated
with obesity-related metabolic disorders and macrophages are known to be major players
in these processes. What is less well recognized is the fact that obesity is associated with
increased risk of a number of cancers, including those of the colon, endometrium and the
breast. In these aforementioned studies, we tested the central hypothesis that chronic
inflammation plays a critical role in the progression and severity of obesity-induced
insulin resistance and hormone-dependent breast cancer progression. Additionally, we
examined the role of MCP-1 expression in an obesogenic inflammatory environment and
furthermore, the association of this chemokine with mammary tumorigenesis.
Overwhelming evidence suggests adipose tissue macrophages participate in
obesity-related complications given their propensity to promote inflammation in the
adipose tissue. In our first study, we examined the role of the macrophage chemokine,
MCP-1, on the inflammatory processes associated with high fat diet-induced obesity.
However contrary to our hypothesis, MCP-1 depletion contributed to increases in
macrophage accumulation, increases in adiposity as well as increases in insulin resistance
and altered glucose sensitivity. As such, we reported a protective role of MCP-1 in the
adipose tissue in response to HFD feedings. Given the ambiguous findings of the role of
MCP-1 in various studies involving obesity-related perturbations, more research is
needed to fully ascertain the role of this chemokine in this processes.
Breast cancer is the second leading killer among women worldwide, as such, the
need to identify novel therapeutic targets is crucial. Clinical studies implicate MCP-1 as
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a major modulator in the progression of mammary tumorigenesis. Macrophages are key
mediators in the connection between inflammation and cancer progression; demonstrated
by the role of MCP-1 as a powerful macrophage chemoattractant. To examine the effect
of MCP-1 in the development and progression of mammary tumorigenesis, we developed
an MCP-1-/- transgenic triple negative breast cancer model. Genetic deletion of MCP-1
expression resulted in decreased tumorigenesis; indicated by decreases in primary tumor
volume and multiplicity, but also a delay in tumor progression demonstrated through
histopathology scoring of the mammary gland. Ablation of MCP-1 expression also
resulted in decreases of inflammatory mediator expression in the localized and tumor
microenvironment. It is known that MCP-1 represents a causal connection between
inflammation and macrophage recruitment and not surprisingly, therefore has an
emergent role in the development of mammary tumorigenesis. However, more research
is required to fully understand the importance and function of MCP-1 in a triple negative
breast cancer microenvironment.
Given that two out of three women in the United States are overweight or obese,
an understanding of the mechanisms that link obesity to breast cancer, and the connection
with menopausal status, is of critical public health importance. There is powerful
evidence that implicates obesity-associated adipose tissue inflammation and aromatase
expression are critically linked. In our final study, we examined mammary tumorigenesis
in response to HFD feedings in a hormone receptor positive model of breast cancer, a
model that closely resembles the etiology of human breast carcinoma. This was done
using both ovary-intact and ovariectomized mice in order to examine the influence of
menopausal status on this response. Results show that HFD-induced obesity exacerbates
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tumorigenesis in the premenopausal model indicated by significant proneoplastic effects
(i.e. primary tumor volume, multiplicity, weight) and advances in histopathological grade
of the mammary gland. HFD treatment of intact mice also led to significant increases in
aromatase and macrophage marker mRNA expression in the gonadal adipose tissue and
an increasing trend of mRNA expression of a macrophage marker in the mammary gland.
HFD feedings in ovariectomized PyMT mice resulted in large increases in adiposity but
had no significant effect on tumorigenesis. This is not only contrary to what we report in
the ovary-intact mice but also surprising considering the amount of literature that
suggests obese postmenopausal women are at a significant increased risk of breast
cancer. Although, aromatase expression has been implicated in modulating multiple
mechanisms in postmenopausal breast cancer, its involvement in tumorigenesis in a
premenopausal model has not been established; thus further research is needed before
mechanism-based strategies can be established.
The prevalence of obesity is rapidly increasing worldwide; thus so are obesityassociated cancer rates. Understanding the pleotropic effects of chronic inflammation
represents a challenging problem. However, gaining increased understanding of the
relationship between inflammation – obesity – and cancer can provide novel insight into
the development of mechanism-based therapeutic strategies.
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